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Abstract 
This thesis discusses two potential in situ-forming hydrogel systems for sustained protein 
release: (i) a chemically cross-linked Hyaluronic acid derivative and (ii) physically cross-linked 
thermo-responsive poloxamer derivatives (PMTs). The synthetic pathway to HA derivatives 
capable of in situ cross-linking by the Cu-I catalyzed azide-alkyne-cycloaddition is introduced. 
Using a commercially available bis-alkyne linker a significant increase in HA MW is achieved. 
However, MW and gel network density are too low to sustain gel dissolution and, hence, to 
serve as sustained release depot. Furthermore, protein stability issues for the generating of 
Cu-I by in situ reduction of Cu-II with ascorbic acid are seen. In contrast, upon heating to 
body temperature PMT gels offer fast hardening, prolonged dissolution time and sustained 
protein release up to several weeks with no indication for protein aggregation and 
degradation. They offer good storage stability and syringeability. Precipitation of the 
employed IGG is reversible and does not affect the protein stability. 
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1. Introduction 
1.1. Biopharmaceutics and sustained release 
Biopharmaceutics such as peptides, proteins and gene vehicles have become more and more 
important within the last decades [1]. Every year several new biopharmaceutics enter the 
market. Search for new targets for biopharmaceutics, as well as for new manufacturing and 
analytical technologies of biopharmaceutics, are ongoing worldwide. Nonetheless, there are 
some drawbacks for biopharmaceutics: (i) high costs for development and production, (ii) 
physical and chemical stability issues like unfolding, oxidation, aggregation and particle 
formation, (iii) mostly parenteral application via injection, resulting in immunogenicity 
concerns and in many cases the need for well-trained medical personnel and/or 
hospitalization [2-6].  
To minimize the injection frequency, which may increase patient compliance and decrease 
hospitalization costs, sustained release could be an option [5, 7-9]. Numerous different 
sustained release systems for biopharmaceutics have already been studied. Among them 
microparticles, implants and hydrogels are the most frequently tested [9-12]. Each system 
offers a unique set of advantages and disadvantages. Microparticles may contain residual 
organic solvent and degradation products with negative impact on protein stability and 
biocompatibility [11, 13-16], and lead to high production costs [9, 14]. On the other hand, a 
large variety of available microparticle forming polymers allows a wide range of drug 
characteristics, drug loading, and release profile [9]. Implants have to be administered 
through needles with large diameter or by surgery, causing pain and reduced patient 
compliance [17], but their less restricted size and the possibility to use non-biodegradable 
materials offers further increased flexibility in drug loading and very long release periods of 
up to several years [9]. In hydrogels drug load and homogeneity as well as the available 
release period are limited (hours to days), and increased viscosity might restrict the ease of 
application [5, 18]. However, hydrogels are especially interesting for the controlled delivery 
of protein pharmaceutics as they offer an aqueous environment and usually mild fabrication 
conditions (aqueous media, room or lower temperature), both being beneficial in terms of 
protein stability and biocompatibility [5, 16, 18]. 
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Hydrogels consist of an insoluble, three-dimensional, porous, hydrophilic polymer network, 
enabling high water content and a semi-solid character [5, 18, 19]. The semi-solid 
mechanical properties originate from physical or chemical polymer-polymer interactions [20-
22]. Hydrogel-forming materials are a heterogeneous group of hydrophilic molecules and 
can be classified by their chemical structure, origin, size, and many other parameters [18, 
23]. Drugs can be physically embedded in the gel matrix and subsequently released by 
diffusion or matrix erosion/disintegration, rendering slowly dissolving, high-density gel 
networks especially interesting  [5, 18]. However, gels with high network density might be 
too stiff for injection, necessitating surgical application [18]. To overcome administration 
issues, so called in situ-forming hydrogels are interesting and emerging systems for 
controlled drug delivery by s.c. or i.m. application [18, 24]. They offer low viscosity prior to 
application, and form mechanically stable gels in situ by a specific physical or chemical 
trigger such as temperature or pH [25]. To achieve in situ-forming hydrogels specific 
limitations have to be overcome: (i) the correct viscosity to enable both syringeability in the 
low viscosity state and sufficient mechanical stability of the formed gel depots at the 
application site of interest; (ii) a fast network-formation speed, limiting diffusion of the 
gel-forming polymer and drug upon injection; (iii) maintaining biodegradation and 
biocompatibility [18, 25]. The main focus of this thesis is to establish an in situ-hardening 
hydrogel for sustained protein delivery. 
1.2. In situ-forming hydrogels by click-cross-linking in presence of protein 
Chemical in situ cross-linking of polymers is characterized by covalent bond formation 
between individual polymer molecules [5, 20].  This leads to a strong increase in molecular 
weight and, ideally, to a well-defined three-dimensional network structure. Furthermore, 
chemically cross-linked molecules offer a reduced solubility compared to linear molecules of 
the same molecular weight [26]. As they have an increased capacity of swelling (i.e., uptake 
of water) compared to unmodified polymers [27-29], chemically cross-linked polymers show 
increased hydrogel forming capacity compared to linear polymers [18]. 
The number of macromolecules which can be utilized for gel formation via chemical 
cross-linking is limited as the chemical cross-linking requires accessible reactive moieties on 
the initial molecule.  In addition, the position of the reactive moiety within the 
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macromolecule is important: terminal functionalities can be used for chain elongation, 
leading to an increased MW but not to actual cross-linking and network formation; instead, 
cross-linking between reactive functional groups on non-terminal monomers within the 
macromolecule chain is required.  Many well-known polymers, like PEG or PLGA, lack 
moieties that fulfil these criteria. Many approaches to introduce suitable chemical properties 
for cross-linking by chemical derivatization of polyacrylates, PEG, polysaccharides such as 
Hyaluronic acid, and peptides or structural proteins have been published [5, 20, 21]. 
1.2.1. Hyaluronic acid 
In this study hyaluronic acid (HA) is chosen, being an intensively studied polymer for 
pharmaceutical and medical applications [30-36]. HA is a highly water soluble linear polymer 
of a β-D-glucuronic acid (GlcUA) and β-N-acetyl-D-glucosamine (GlcNAc) disaccharide called 
Hyaluronan (Fig. 1.1). HA is biocompatible and biodegradable, and is commercially available 
in molecular weights ranging from a few kDa to several MDa [37-39]. Low molecular weight 
species < 10 kDa can interact with specific Hyaluronan receptors, inducing angiogenesis [39]. 
Also a pro-inflammatory effect of low molecular weight HA species, but excellent safety 
profile for the medium and high molecular weight species, are reported [40, 41]. There is no 
evidence for negative effects on protein stability by HA. In contrary, Meyer et al. showed 
that the stability and activity of a recombinant granulocyte colony stimulating factor is 
maintained upon sustained release from viscous HA solutions within four to five days in vivo 
[42]. HA was also shown to sustain peptide release for hours to days [43, 44]. This makes 
medium to high MW Hyaluronic acid a preferred hydrogel platform for protein 
pharmaceutics [32]. In this study a 100 kDa HA quality is chosen.  
However, HA gels readily disintegrate in aqueous body fluid, and HA has a short half-life [32]. 
In order to enhance sustained protein release properties HA has been modified, e.g. by 
esterfication, to yield an increased half-life and reduced water solubility [45-48]. This makes 
HA an interesting model for chemical cross-linking in presence of protein, developing an 
injectable, protein loaded hydrogel.  
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Fig. 1.1: The Hyaluronan monomer 
HA contains two types of accessible reactive moieties: hydroxyl groups and free carboxylic 
acid groups. Reactions available to link these functionalities, e.g. via active-ester 
intermediates like NHS-esters, will lead to significant intramolecular cross-linking as well as 
cross-reactions in presence of proteins, as most proteins also contain hydroxyl and 
carboxylic acid groups. Consequently, HA has to be derivatized to introduce a new 
functionality that allows selective cross-linking reactions in presence of protein. Several 
methods to introduce a large diversity of functional groups into HA are reported in literature 
[45, 49-56]. For the cross-linking of HA in presence of protein introducing alkyne and azide 
groups is especially attractive. Those two functional groups can undergo a [3+2] 
cycloaddition (or 1,3 dipolar cycloaddition) to form triazole rings [57-60]. This reaction is 
frequently utilized in polymer and material sciences [58, 61-63].  
1.2.2. Click-cross-linking HA 
To start the azide-alkyne cycloaddition an activation of the alkyne is required – which can be 
achieved by elevated temperature, metal catalysis (mostly Cu-(I) is used), or by usage of 
permanently activated electron-deficient or stained cyclic alkynes [57, 59, 61, 64-72]. The 
use of elevated temperatures may result in protein damage. Furthermore, this reaction is 
not regioselective [59]. The Cu-(I) catalyzed azide-alkyne cycloaddition (CuAAC, also referred 
to as Huisgen-Reaction), is one of the most frequently used click-reactions [59, 70]. It is 
irreversible, offers high reaction rates and yields in aqueous systems, and is highly selective 
(Fig. 1.2). As neither native peptides, proteins or nucleic acids contain azide or alkyne 
moieties, no side reaction with biopharmaceutics occurs [73]. Successful usage of CuAAC in 
O
NH
OO
OH
OH
CH3
O
O
OH
OH
O
OH
O
GlcUA GlcNAc
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living environments is reported in literature, despite the potential toxic effects of copper 
ions [60, 65, 73, 74]. The metal-free alternatives might further enhance biocompatibility due 
to the lack of metal ions, but require more complex alkyne-structures, e.g. strained cyclic 
alkynes [75-79], which are less accessible than terminal alkynes. Triazoles, the final product 
of the azide-alkyne cycloaddition, are inert and biocompatible [80]. Thus, the CuAAC is an 
appropriate reaction to cross-link azide or alkyne derivatives of HA in presence of protein. 
For later studies, a transition to metal-free alternatives, further enhancing the safety profile, 
could be possible.  
 
Fig. 1.2: The Cu-I catalyzed azide-alkyne cycloaddition 
To cross-link HA by CuAAC three options are possible: (I) prepare and cross-link two HA 
qualities, one bearing azide groups, the other one terminal alkyne groups [81]; (II) synthesise 
and cross-link HA derivatives with a mixture of both azide and alkyne functionalities on each 
molecule, which, however, would most likely result in substantial intramolecular 
ring-formation; (III) attach either azide or alkyne to HA and add a corresponding bis-azide or 
bis-alkyne linker molecule [82]. Major benefit of the latter method is the flexibility of the 
linker molecule (in both chemical structure and concentration), which provides control over 
the mesh density formed by cross-linking. This mesh density is crucial to embed and release 
protein from the gel matrix and needs to be adjusted properly [5, 26, 83, 84].  
To generate controlled release formulations based on cross-linked HA, the cross-linking has 
to induce a significant increase in molecular weight and, maybe, viscosity. The cross-linked 
HA has to show a reduced solubility in comparison to unmodified HA to become a potential 
controlled release hydrogel material with adequate sustainability in the body. In this study 
100 kDa HA was modified with 11-Azido-3,6,9-trioxaundecane-1-amine (Az3OA) to yield 
azido derivatized HA (dHA, Fig. 1.3) with a known degree of substitution (DoS) and, thus, 
number of azide residues per HA chain. The dHA concentration was set to 2.5 mg/ml – at this 
concentration, the viscosity is still low enough to ensure easy handling, and an increase in 
viscosity due to cross-linking should be easily notable. 
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Fig. 1.3: Chemical structure of an Hyaluronan monomer derivatized with Az3OA. 
The linker based approaches published in literature use low molecular weight lipophilic 
dialkyne linkers, leading to harsh reaction conditions and the use of organic solvent [49, 82]. 
Also the shortness of the linker molecules appears less suitable for the entrapment of large 
molecular weight components like proteins [5, 26, 83, 84]. Therefore, the more hydrophilic 
Alkyne-PEG-Alkyne (APA) linker with 1 kDa MW was chosen (Fig. 1.4). Its solubility in water is 
still limited to approx. 0.5 mg/ml, corresponding to approx. 1.0 mM alkyne. Increasing the 
MW of APA might increase the mass solubility [mg/ml] due to an increased number of 
hydrophilic ethyleneoxide blocks. Also the molar solubility [mM] may be increased. 
However, for the intended cross-linking process the alkyne concentration is more relevant 
and the chosen APA represents an acceptable compromise. 
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Fig. 1.4: The APA linker 
Usually, CuAAC reactions and their copper-free derivatives use large excess of alkyne over 
azide [63, 70, 85]. For cross-linking dHA this large excess of alkyne would be 
disadvantageous, rendering a high degree of only single-sided linker attachment to HA. A 
high azide:alkyne ratio, however, slows down the reaction rate [63, 70, 85]. As a compromise 
an azide:alkyne ratio of 1.2 was chosen.  
As common for CuAAC systems, ascorbic acid was used to generate Cu+ from CuSO4 in situ 
and both copper and ascorbic acid were used in large molar excess compared to the alkyne 
[63, 70, 86]. Cross-linking was carried out at 20 °C in PBS, as this is reported to yield 
sufficient reaction rate and efficacy of the cycloaddition without negative impact on protein 
stability [61, 64, 70, 72].  
1.3. In situ-forming thermo-responsive hydrogels 
Physical in situ cross-linking of hydrogel forming polymers is based on varying the strength of 
inter- and intramolecular hydrophilic and lipophilic interactions of the polymer chains in 
solution, inducing swelling or de-swelling of the polymer matrix [18, 22, 25, 87]. One of the 
most intensely studied class of physically cross-linked hydrogels are thermo-responsive, or 
thermo-reversible, systems [5, 25, 87]. Most thermo-responsive hydrogels are based on 
amphiphilic block-co-polymers [88]. Important examples are poloxamers, 
Poly(N-isopropylacrylamid) (pNiPAAm), Poly(butyleneterephthalate-polyethyleneoxide) 
(PolyActive®), and Poly(lactic-co-glycolic)-polyethyleneoxide block-co-polymers [5, 25, 89].  
Thermo-reversible hydrogels are characterized by the lower critical solution temperature 
(LCST). For systems with polymer concentration higher than approx. 10 % (w/v) instead LCST 
the term volume phase transition temperature (VPTT) is often used [90]. At this temperature 
polymers change from a solubilised, swollen sol state into a more condensed, precipitated 
gel state [25, 90]. The condensed state is characterized by organized molecular patterns such 
as micelles or lyotropic crystalline structures [88, 91-93]. Water is present in hydrophilic 
CH
O
O
CH
21
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domains or between hydrophilic domains of the condensed state [25, 90]. The 
rearrangement is caused as hydrogen bonding between the polymer and water becomes 
unfavourable compared to polymer–polymer and water–water interactions [87]. Micelles 
might already be present in the sol state but their concentration increases roughly linearly 
with temperature, until either saturation is reached, where all polymers are part of a 
micelle, or the volume density of micelles is so high that they lock into a crystalline structure 
[92]. The process of micelle formation and subsequent micelle packaging is also described in 
[94-96] and illustrated in Fig. 1.5.  
 
Fig. 1.5: Schematic image of block-co-polymer (e.g. poloxamer, left) and chain-elongated 
block-co-polymer (e.g. PMT, right) forming micelles and packed micelle structures upon 
warming above the LCST.  
Increasing the temperature even further leads to decreasing intermicelle interaction [92] 
and, therefore, gel weakening. Obviously, besides temperature also the polymer 
concentration plays an important role [92, 96-99]. In literature several examples of gel 
formation by thermo-responsive polymers can be found. E.g. poloxamer 403 (5.8 kDa total 
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MW, consisting of 30 % w/w PEO attached to a 4 kDa PPO block) forms gels at approx. 20 % 
(m/m) concentration and  40 °C by  formation of cubic phases [100]. At lower and higher 
temperatures gels can still be formed using higher poloxamer 403 concentrations of up to 
40 %. To form gels poloxamer 407 (12.6 kDa with 70 % PEO and a 4 kDa PPO block) requires 
slightly lower gel concentration than poloxamer 403, approx. 15 % at 37 °C [99, 100]. For 
PLGA-PEG polymers a concentration of 23 %  is reported to yield mechanically stable gels 
between 30 and 40 °C [101]. Garripelli et al. showed that 25 % chain-elongated poloxamer 
304 (5.9 kDa, 40 % PEO, 3 kDa PPO block) and 205 (4 kDa, 50 % PEO, 2 kDa PPO block) 
polymers show a strong increase in viscosity at approx. 20 °C [102].  
1.3.1. Thermo-responsive hydrogels for controlled protein delivery 
Many studies have been performed to analyse the suitability of thermo-responsive 
hydrogels for controlled drug release purposes, specifically proteins [93, 103-105]. Johnstan 
et al. achieved a release of Interleukin-2 (IL-2) from a poloxamer 407 gel for several hours 
both in vitro and in vivo [106]. BSA delivery with pNiPAAm-PEG gels continued for approx. 
5 days in vitro [107]. Sustained growth hormone release can be achieved by PLGA-PEG-PLGA 
gels [108]. Thus, the hydrogels exhibit a rather fast release compared to other parenteral 
depot systems like PLGA microparticles or implants [5]. 
As poloxamer is approved by the FDA for parenteral use and products including this 
excipient (e.g. RheotRX® or Orencia®) are marketed, it is a highly interesting system for 
further optimization [93, 109]. Although poloxamer 407 gels dissolve in PBS in less than two 
days even at concentrations above 30 % [17] they are described as potential in situ gelling 
controlled release vehicle for hGH, Insulin, GnRH or IL-2 [87, 106]. However, poloxamer 407 
gels render only release times of less than 24 h [99]. To enhance the mechanical stability and 
slow down erosion and, thus, drug release, poloxamer molecules can be grafted to less 
water soluble materials like polyacrylates or PLGA [99, 110, 111]. Thereby biodegradability 
may get lost and copolymers that are not approved by the authorities are formed. 
Other studies increased the MW of poloxamer 407, 205 or 304 by chain-elongation to trimers 
and tetramers [102, 112, 113] to yield prolonged release times of days to weeks. This is a 
very promising approach, as long as the final MW of polymers or their biodegradation 
products remain low enough to ensure renal extraction of the non-biodegradable PEO/PPO 
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(approx. < 40 kDa) [114, 115]. The thermo-responsive hydrogels studied in this thesis follow 
the same idea, employing oligomers of the less water soluble poloxamer 403. The oligomers 
are designed to increase gel half life and protein release to more than one week while 
maintaining syringeability through 20 G (or smaller) needles. 
Fig. 1.5 demonstrates the changes induced by poloxamer chain-elongation. The micellar 
network becomes additionally covalently linked. This micelle bridging causes an increase in 
mechanical strength of the formed gel and less flexible pores with limited macromolecular 
diffusion [116-119]. 
An additional requirement for thermo-responsive hydrogels is protein stability within the 
system. Due to the aqueous environment adequate stability is to be expected and literature 
typically states good protein stability [99, 108, 120, 121]. However, the integrity of protein 
pharmaceutics within the hydrogel sample (preparation), as well as the activity and safety of 
released API have to be evaluated critically [4, 24, 122].  
1.3.2. PolyMaterials Thermopolymers (PMTs) 
The Thermopolymers by Polymaterials AG (PMTs) are derived from poloxamer by 
chain-elongation using diisocyanates (Fig. 1.6). The urethane groups linking separate 
poloxamer molecules undergo hydrolysis under physiological conditions [123]. Poloxamers 
themselves are regarded as fast eroding and non-toxic in s.c. and i.m. parenteral 
formulations [87, 99]. Furthermore, poloxamer can be extracted by the kidneys [87]. Thus, 
PMTs can be considered biodegradable and biocompatible. 
 
Fig. 1.6: Chemical structures of diisocyanates (DIC) and corresponding bifunctional urethane 
linker (BUL). From left to right: Butyldiisocyanate (BDI), Hexamethylene diisocyanate (HDI) 
and H12-4,4’-methylene diphenyl diisocyanate (MDI). 
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1.4. Aims 
The aim of this thesis is to establish in situ-forming, injectable depot formulations for protein 
pharmaceutics on the basis of either click-cross-linked HA or thermo-responsive PMT gels. 
Release periods of days to weeks, biocompatibility, biodegradation and maintained protein 
stability are aimed for. As the required HA derivative is not commercially available, the 
derivatization process of HA is discussed. To characterize both potential hydrogel systems 
the ease of preparation and application, gel hardness and stability, as well as protein release 
and integrity are studied. The results of both hydrogel systems are critically discussed and 
compared with data for established materials.  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Solvents 
Throughout the thesis water from an Elga (Celle, D) PureLab Plus or a Sartorius (Göttingen, 
D) Arium system was used. Sulfuric acid (Aldrich, Taufkirchen, D) is 98 %, Ethanol (Th. Geyer, 
Renningen, D) is 96 %. DMSO and THF (both Fluka, Buchs, CH) are analytical grade and dried 
over molecular sieve 4 Å (Sigma, Taufkirchen, D). 0.1 and 1.0 M HCl and NaOH (all VWR, 
Ismaning, D) are analytical grade standard solutions.  
2.1.2. Salts, buffers and reagents 
Table 2.1 shows a list of salts and reagents, their corresponding provider and grade. APA and 
EDC were stored under nitrogen atmosphere at -20 °C. Az3OA was stored under nitrogen 
atmosphere at 2-8 °C. All other substances were stored at RT. 
 
Table 2.1: List of salts and reagents, their corresponding provider and grade. 
 
Two different buffers were used: 10 mM isotonic PBS pH 7.2 and 50 mM MES buffer pH 4.0. 
If not noted otherwise, they will be referred to as “PBS” and “MES buffer” in the remaining 
text. PBS contained 335.9 mg NaH2PO4, 1007.9 mg Na2HPO4 and 7,595 mg NaCl per litre. 
MES buffer contained 9.76 g MES per litre. pH was adjusted at RT by drop wise addition of 
either HCl or NaOH under continuous stirring. Buffers were filtered (0.2 µm PES 50 mm Ø by 
Sartorius) prior to usage.  
Name Provider Grade
NaCl Fluka (D) and Aldrich (D) analytical
NaH2PO4 waterfree Sigma (D) analytical
Na2HPO4 waterfree Fluka analytical
CuSO4 pentahydrate Sigma analytical
Ascorbic acid Sigma reagent
2-(N-morpholino)ethanesulforic acid (MES) Sigma analytical
N-Hydroxysuccinimide (NHS) Aldrich ≥ 98 %
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) Sigma ≥ 99 %
11-Azido-3,6,9-trioxaundecane-1-amine (Az3OA) Aldrich ≥ 90 %
Alkyne-PEG-Alkyne 1.0 kDa (APA) Creative PEGworks (US) ≥ 98 %
Carbazole Sigma ≥ 95 %
Sodium Dodecyle Sulfate (SDS) Sigma ≥ 99 %
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Further solutions used were saturated NaCl, 1 % SDS, 5 mM CuSO4 (in PBS), 50 mM ascorbic 
acid (in PBS), 1 mg/ml Carbazole (in Ethanol) and 1 mg/ml APA (in DMSO). Saturated NaCl 
und 1 % SDS were stored at RT. All other solutions were stored at 2-8 °C and allowed to 
reach RT prior to usage.  
2.1.3. Proteins 
Spray dried lysozyme from hen egg white (22,300 units per gram, MW 14.3 kDa) was 
purchased by Dalian Greensnow (Dalian, CN) and stored at 2-8 °C. 100 mg/ml lysozyme stock 
solutions in PBS were freshly prepared and filtered (0.2 µm 25 mm Ø PES syringe filters by 
VWR).   
A 2 mg/ml solution in PBS of a recombinant human IgG1 with approx. 150 kDa MW was used 
as bulk. This solution was concentrated in PBS to approx. 20 mg/ml using VivaFlow 50 PES 
(Satrorius), filtered (0.2 µm 25 mm Ø PES syringe filters), and further concentrated to 
approx. 100 mg/ml using 20 ml VivaSpin PES with mwco 30 kDa (Sartorius).  
2.1.4. Hyaluronic acid and derivatives 
100 kDa and 1.0 MDa sodium hyaluronan API grade (HA) were purchased from Shiseido 
(Tokyo, JP). Three different HA derivatization processes were carried out, each using approx. 
500 mg HA and a final lyophilisation step as described in [81] (primary drying at -22 °C and 
160 mTorr for 20 h, secondary drying at 20 °C and 75 mTorr for 22 h using an Epsilon 2 by 
Martin Christ, Osterode, D). Corresponding HA derivatives are depicted as dHA-1 to 3 in the 
following text. Yields (w/w) were calculated as total mass after freeze-drying divided by the 
sum of total HA mass and Az3OA mass employed.  
dHA-1 was obtained as described in [81] by dissolving 100 kDa HA in approx. 20 ml MES 
buffer. This solution was transferred to a solution of 232 mg EDC and 139 mg NHS in 5 ml 
MES buffer under stirring. 480 µl Az3OA were added and the reaction mixture was incubated 
at RT for 24 h under continuous stirring and subsequently dialyzed for 24 h against 4 l 
saturated NaCl and finally three times for 24 h against 4 l water using a 14 kDa mwco 
cellulose membrane by Roth (Karlsruhe, D).  
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For dHA-2 dialysis was replaced by centrifugation of the reaction mixture using VivaSpin 20 
with 10 kDa mwco (Sartorius). The material was concentrated and washed with 5 ml 
saturated NaCl and finally water. 
For dHA-3 70 ml MES buffer, 489 mg EDC, 293 mg NHS and 1010 µl Az3OA were used. 
Purification was analogue to dHA-2. 
2.1.5. PMTs and poloxamers 
PolyMaterials Thermopolymers (PMTs) were provided by PolyMaterials® AG (Kaufbeuren, 
D). They were derived from poloxamers purchased from Sigma. Molecules of one type of 
poloxamer, or defined mixtures of several poloxamers, respectively, were covalently linked 
to undergo chain-elongation in an organic solvent using a special catalyst as well as three 
different diisocyanates (DIC) as linkers: Hexamethylene diisocyanate (HDI), 
H12-4,4’-methylene diphenyl diisocyanate (MDI) and Butyldiisocyanate (BDI). Thus, complex 
multiblock copolymers of “ABAC” building block structure with A being PEO, B PPO and C a 
small bifunctional urethane linker were formed. Each polymer was subsequently purified 
and dried. Polymaterials certified PMTs to be free of catalyst, unreacted DIC, organic solvent 
and other relevant impurities. Biodegradation to poloxamer remnants by urethane 
hydrolysis allows renal extraction of the material.  
Table 2.2 lists the PMTs used throughout this study. The short name given therein is of a XyZ 
type, with X indicating the DIC (H for HDI, M for MDI and B for BDI), y representing the 
average number of poloxamer unimers per PMT (based on MW information provided by 
PolyMaterials), and Z depicting the poloxamer type(s) used (P referring to poloxamer 403, F 
to poloxamer 407, f to poloxamer 308, respectively). E.g. H6P stands for 6 poloxamer 403 
(6P) unimers linked by HDI (H). H1.5P1.5F1.5f also used HDI as linking DIC; but molecules of 
this PMT contained on average 1.5 poloxamer 403 (1.5P) units, 1.5 poloxamer 407 (1.5F) 
units and, at the same time, 1.5 poloxamer 308 (1.5f) units. As reference materials 
unmodified poloxamer 403 (Sigma) and poloxamer 407 (BASF, Ludwigshafen, D) were used. 
Their corresponding MW was 5.8 kDa (403) and 12.6 kDa (407), respectively. PMTs were 
stored at -80 °C and allowed to reach RT prior to processing. Unmodified poloxamers were 
stored at RT. 
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Table 2.2: list of PMT batches. 
To generate PMT or poloxamer gels, an adequate amount of dry polymer was weighted into 
a 2 or 5 ml male luer lock syringe (Braun, Melsungen, D) with removed plunger. If required, 
proper amounts of 1, 4 or 20 kDa polyethyleneglycole (PEG, all by Aldrich), or 2 or 4 kDa 
polypropyleneglycole (PPO, both by Aldrich) were added to the dry PMT/poloxamer. Using 
female-female luer adapters (Braun), a second, empty male luer lock syringe of identical size 
was connected. The necessary volume of cooled (2-8 °C) PBS was added on top of the 
polymer in the open part of this two-syringe-system. If required, also adequate amounts of 
cooled (2-8 °C) lysozyme, IgG or FITC-Dextran 150 kDa (Aldrich) stock solutions were added. 
The plunger was reinstalled, the air removed and the two-syringe-system was cooled to 
2-8 °C for 15 min. Subsequently, polymers were dissolved and solutions homogenised by 
repeated transfer from one syringe to the other and back for approx. 2 min. After this cycle 
of cooling and homogenisation was repeated for 3-4 times samples were incubated at 2-8 °C 
for 12 h. This process was repeated until the polymers were completely dissolved and 
samples were homogenous. Subsequently, all samples were stored at 2-8 °C. 
2.1.6. Fluorescence labelled dHA 
Atto 655 labelled 100 kDa dHA was prepared by incubating 4 nmol of the corresponding dHA 
with 200 nmol Atto 655 alkyne (Atto Tec, Siegen, D) in 100 µl PBS with 0.2 mM CuSO4 and 
2.0 mM ascorbic acid in the dark at RT for 3 d and subsequent dialysis against water by 
centrifugation using VivaSpin 500 with mwco 5 kDa. The excess of dye, copper and ascorbic 
acid as well the long reaction times were necessary to secure complete labelling of all azide 
Short name Batch number MW [kDa]
H4P GAM19 26
H6P AP1384 / AP1976 36
H7P AP2102 43
H8P AP1977 45
H11P GAM23 64
M6P AP1975 37
B7P AP1476 / AP1966 42
H5P2F GAM36 51
H2.5P2.5F AP2047 48
H1.5P1.5F1.5f AP2087 49
H4F AP2035 55
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moieties present in dHA. As reference 100 kDa HA was processed analogously. Filtrates were 
collected and supernatant volume was restored to 100 µl with water. Dye concentration of 
the reference sample filtrate was monitored by fluorescence (ex. 663 nm, em. 684 nm) using 
a Cary Eclipse Fluorescence Spectrophotometer (Varian, Palo Alto, US) and the 
centrifugation procedure was repeated until no more dye was detected in the reference 
filtrate (approx. 10 to 15 times). 
2.1.7. Cross-linked HA 
dHA with known DoS (refer to chapter 2.2.3.), APA, CuSO4 and ascorbic acid were mixed in 
PBS to yield final concentrations of 2.5 mg/ml dHA, 0.2 mM Cu2+ and 2.0 mM ascorbic acid as 
well as an azide to alkyne ratio of 1.2 : 1.0. This mixture was incubated at RT for 3 days to 
achieve cross-linked HA (cHA). Excess of azide as well as copper and ascorbic acid were 
necessary to suppress single-sided linker binding. 
2.2. Methods 
2.2.1. Determination of protein and FITC-Dextran concentration 
To determine protein concentrations an Agilent (Waldbronn, D) 8453 UV-Vis spectrometer 
was used.  Samples were analysed in quartz cuvettes at 280 nm and 20 °C at absorbance 
values between 0.1 and 1.0. ε280 was 2.64 ml mg
-1 cm-1 for Lysozyme and 1.5875 ml mg-1 cm-1 
for IgG. 
Alternatively, concentration of protein monomers, oligomers and fragments was analysed by 
HPSEC using either a Tosoh (Stuttgart, D) TSK Gel G5000 PWXL 7.8 x 300 mm (for lysozyme, 
FITC-Dextran and IgG) or a Tosoh TSK Gel SuperAW 6000 6.0 x 150 mm column (only IgG) 
and one of two different Agilent HPSEC systems with each Tosoh SWXL guard column, 
0.333 ml/min PBS, injection of 50 to 100 µl cooled (5 °C) samples using a 100 µl dosing loop 
at 100 µl/min followed by needle wash with PBS, column temperature 20 °C, UV absorbance 
detection at 280 nm, manual peak integration with Agilent ChemStation for LC systems B.02 
and quantification against a freshly prepared concentration series of the corresponding 
material. The first system was used for protein samples with known or estimated 
concentration > 0.1 mg/ml and employed 1100 series quartenary pump G1311A, sample 
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thermostat G1330A, autosampler G1329A, column compartment G1316A and DAD G1315A. 
The second system employed was composed of a 1200 binary pump G1312A, a sample 
thermostat G1330B, an autosampler G1329A, a column compartment G1316A, a VWD 
G1314B and an HP (Palo Alto, US) FAD 1046A (ex. 280 nm, em. 315 nm for protein, ex 
492 nm, em. 518 nm for FITC-Dextran). FAD signals were used for protein concentrations 
< 0.1 mg/ml as well as for FITC-Dextran quantification, otherwise VWD signals were used. 
2.2.2. Determining the degree of substitution of dHA 
To determine the degree of substitution (DoS) of derivatized HA (dHA) the corresponding 
dHA was labelled with Atto 655 nm fluorescent dye (refer to chapter 2.1.6.). After restoring 
to 100 µl volume both sample and reference supernatant were analysed with an Agilent 
8453 UV-Vis spectrophotometer with Agilent 89090 temperature control unit at 663 nm and 
20 °C. ε663 was 1.25 * 10
5 mol l-1 cm-1. Dye found in the reference supernatant was 
considered as unspecific binding.  
The number of specifically bound dye molecules represents the number of azide moieties 
per dHA molecule. To determine the DoS this number of azide moieties was correlated with 
the average number of Hyaluronan monomer per 100 kDa HA molecule (274).  
2.2.3. HA quantification by modified carbazole method 
Based on the method using carbazole to quantify uronic acid species by Dische et al. as well 
as modifications of this method published in later years [124-126] 30 µl HA samples in PBS 
were mixed with 160 µl sulfuric acid in 2 ml secure closure caps (Eppendorf, 
Wesseling-Berzdorf, D) and incubated in an aluminium heating block at 90 °C for 30 min. 
After cooling to RT 12 µl 1 mg/ml Carbazole in ethanol were added and the sample was 
incubated in the dark at RT for 2 h. Colour intensity was detected at 530 nm in a 96 well 
quartz well plate using a FLUOstar Omega (BMG Labtech, Ortenberg, D). Employing a 
concentration series of 100 kDa HA as well as comparing 100 kDa with 1 MDa HA this 
method was found to be applicable from approx. 30 µg/ml to 1 mg/ml HA, but only 
semi-quantitative information is gained.  
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2.2.4. Molecular weight analysis of HA species 
To gain MW information of HA, dHA and cHA, 100 µl 2.5 mg/ml samples of HA, dHA or cHA 
were injected to an HPSEC system employing Tosoh SWXL guard column followed by a Tosoh 
TSK Gel G5000 PWXL 7.8 x 300 nm and a Tosoh TSK Gel SuperAW 6000 6.0 x 150 mm using 
an Agilent 1200 binary pump G1312A at 0.6 ml/min PBS, sample cooling to 5 °C with 1200 
sample thermostat G1330B, a 100 µl dosing loop at 100 µl/min and subsequent needle wash 
with PBS by a 1200 autosampler G1329A and 1200 column compartment G1316A at 20 °C. 
After discarding the first 7 ml elution volume 0.3 ml samples were collected manually until 
an elution volume of 10 ml followed by 0.6 ml samples until 14.2 ml elution volume were 
reached. HA concentration in each sample was subsequently determined by the modified 
carbazole method (refer to chapter 2.2.3). 
Alternatively, 200 µl 2.5 mg/ml samples of HA, dHA or cHA were centrifuged for 1 h using 
VivaSpin 500 with either 10 or 300 kDa mwco, respectively. HA concentration in both 
supernatant and filtrate were subsequently analysed by the modified carbazol method (refer 
to chapter 2.2.3). 
2.2.5. Molecular weight analysis of PMTs 
Using an Agilent HPSEC system with 1100 quartenary pump G1311A at 1 ml/min THF, SDV 
guard column, SDV 100 Å and SDV 10,000 Å (all by PSS, Mainz, D), 1100 sample thermostat 
G1330A at 5 °C, 1100 autosampler G1329A with 100 µl dosing loop at 100 µl/min and needle 
wash in THF, 1100 column compartment G1316A at 20 °C, 1200 RID 1362A and stainless 
steel capillaries (VWR), 75 µl samples of approx. 5 mg/ml PMT with 1 % Acetone in THF were 
analysed. Relative retention times against acetone as internal standard were calibrated with 
a Polystyrene ReadyCal Kit by PSS.  
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2.2.6. Viscosity of HA species 
An mVROC viscosimeter (RheoSense, San Ramon, US) equipped with an A05 chip (50 µl flow 
channel) at 25 °C was used. Samples were transferred to 250 µl Hamilton syringes (Fisher 
Scientific, Hampton, US) and equilibrated for 2 min to flush the instrument with 50 µl 
samples at 50 µl/min. Subsequently, measurements were performed in triplicates of 50 µl at 
50 µl/min for each sample.  
2.2.7. Gel strength of PMT/poloxamer gels 
To analyse the hardening profile of PMT/poloxamer gels 0.5 g gel were placed on the Peltier 
element (10 °C) of an Anton Paar Physica (Ostfildern, D) MCR 100 rheometer equipped with 
a 50 mm 1 ° stainless steel cone. The cone tip was then placed 42 µm above the Peltier 
surface and excess gel was removed with soft tissue (VWR). After a hold time of 5 min a 
temperature ramp from 10 to 45 °C at 1 °C/min was employed and storage and loss modulus 
(G’ and G’’) were determined in oscillating mode at f = 1 Hz and γ = 0.5 % every 30 sec. 
Alternatively, a TA.XT plus texture analyser (Texture Technologies, Hamilton, US) equipped 
with a 4.2 mm stainless steel punch was used. 0.5 g of each sample were transferred to a 
1.5 ml secure closure cap (Eppendorf), cooled to 2-8 °C to secure a smooth and homogenous 
surface, subsequently placed in an aluminum heating block at a defined temperature 
(21-45 °C) with a hold time of 10 min before measurement. The punch penetrated into the 
gel for 40 s with a constant test speed of 0.05 mm/s and the maximal indentation force is 
considered the penetration resistance of this sample at the specific temperature.  
2.2.8. Disintegration time of PMT gels 
Approx. 0.5 g of cool (2-8 °C) gel were transferred to the wall of a lying 37 °C warm 50 ml 
tube (VWR) and hardened by incubation at 37 °C for 15 min to yield pre-formed depots. The 
tube was erected and placed in a shaking water bath (f = 1 Hz) at 32, 35, 37, 39 or 42 °C, and 
20 ml of 32, 35, 37, 39 or 42 °C warm PBS, respectively, were added. Alternatively, depots 
were formed in situ by injection (1ml syringe and 4 cm 20G needle, both Braun) of 0.5 g cool 
(2-8 °C) gel into 20 ml PBS at 37 °C. Depot erosion was monitored visually on a daily basis for 
four days and then weekly for another twelve weeks. 
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2.2.9. Cloud points of PMT gels 
Approx. 1 g of 2-8 °C gel was transferred to a 1.5 ml quartz glass cuvette, equilibrated at 
2-8 °C for 15 min and analysed in an Agilent 8453 UV-Vis spectrometer equipped with an 
Agilent 89090 temperature control unit. After a hold time of 5 min at 10 °C a temperature 
ramp from 10 to 45 °C at 1 °C/min was employed and absorbance at 350 nm was measured 
every 30 sec. As most samples reached the instrument’s detection limit, no mathematical fit 
of data curves could be applied. Instead, cloud points were defined as the lowest 
temperature with absorbance > 2.   
2.2.10. Injection forces of PMT gels 
1 ml luer lock syringes (Terumo, Eschborn, D) were filled with approx. 0.7 ml cool (2-8 °C) 
gel, equipped with 4 cm 20 G stainless steel needles (Braun), and allowed to reach RT. 
Subsequently, they were placed in a stand under a TA.XT plus texture analyser (Texture 
Technologies, Surrey, GB) equipped with a plastic punch (square area 1.13 cm²) and gels 
were injected into air at 100 µl/sec and RT.  
2.2.11. Protein precipitation in PMT gels 
To study protein precipitation in PMT gels protein loaded PMT gels were prepared (refer to 
chapter 2.1.5) and at defined time points images were taken. Alternatively, 0.5 g freshly 
homogenized gel were transferred to 1.5 ml secure closure caps (Eppendorf) and centrifuged 
at 5 °C and 10 kG for 60 min. Protein concentration in both supernatant and filtrate was 
determined by UV (chapter 2.2.2) at 5 °C. 
2.2.12. Release of protein and FITC-Dextran from PMT gels 
In a standard set-up approx. 0.5 g of cool (2-8 °C) gel, containing either defined amounts of 
lysozyme, IgG or FITC-Dextran, were transferred to the wall of a lying 37 °C warm 50 ml tube 
(VWR) and hardened by incubation at 37 °C for 15 min to yield pre-formed depots. The tube 
was erected and placed in a shaking water bath (f = 1 Hz) at 37 °C. To initialize release 20 ml 
of 37 °C warm PBS were added.  Alternatively, pre-formed depots were processed at 35 or 
39 °C, or depots were formed in situ by injection of 0.5 g cool (2-8 °C) gel through 4 cm 20 G 
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stainless steel needles into 20 ml PBS at 37 °C. In each case samples of 200 µl incubation 
liquid were sampled without replacement at defined time points and analysed by HPSEC. 
After the last sampling point depots were liquefied and dissolved in the remaining acceptor 
medium by cooling to 2-8 °C for 12 h and a final sample of 200 µl was taken and analysed. 
For further protein stability testing, some release experiments were performed under 
laminar air flow (LAF) conditions with pre-formed depots at 37 °C using pre-rinsed tubes. At 
defined time points samples of 2.0 ml were taken and replaced by 2 ml fresh 37 °C warm 
PBS.  
2.2.13. Intrinsic fluorescence 
200 µl samples taken from protein stability release experiments as well as 200 ml samples of 
freshly prepared IgG solution were transferred to 96 deepwell fluorescence plates (NUNC, 
Rosklide, DK). A Cary Eclipse Fluorescence Spectrophotometer (Varian) was used to detect 
intrinsic fluorescence emission spectra from 310 to 450 nm at constant excitation 
wavelength of 280 nm (5 nm threshold). Fluorescence spectra of freshly prepared IgG 
solutions (representing native IgG) and release samples were compared to determine 
alterations of secondary protein structure. 
2.2.14. Turbidity, visible and sub-visible particles 
Visible particles in the release sample were detected at RT following Ph.Eur. 2.9.20. A 
NEPHLA laboratory turbidimeter with 1.8 ml test tubes (all Hach Lange, Düsseldorf, D) 
operating at 860 nm and 90 ° scattering angle was used to determine sample turbidity. 
Results were depicted as formazine nephelometric units (FNU). Subvisible particles > 1, > 10 
and > 25 µm were analysed via light obscuration with a PAMAS SVSS-C (PAMAS, Rutesheim, 
D). The instrument was flushed with 1 ml 1 % SDS and subsequently 3 ml water prior to 
usage. For each measurement 0.5 ml sample were used to flush the system, followed by 
particle measurement of three 0.3 ml sample fractions and another cleaning step with 1 ml 
water. After three measurements initial cleaning with SDS and water was repeated. Particle 
counts for three sample fractions of each measurement were averaged. 
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3. Click-cross-linked hyaluronic acid gels 
3.1. Preparation and characterization of derivatized HA 
By introducing azide groups to the carboxylic acid moieties of 100 kDa HA via active-ester 
synthesis three batches of derivatized HA (dHA-1 to 3) were prepared. A degree of 
substation (DoS) of approx. 12 % is aimed for, corresponding to approx. 33 azide moieties 
per HA chain. This high number of azide groups would offer sufficient binding sites for linker 
molecules to foster a coherent network formation. This significant introduction of azide 
moieties and the corresponding reduction of free carboxylic groups are not considered to 
change the overall properties of HA [127]. However, a high DoS may trigger the undesired 
side reaction of intramolecular ring formation. Thus, there is no linear correlation between 
DoS and effective degree of cross-linking. Furthermore, if the DoS is too high, the resulting 
network could become too dense for protein release [83, 84].  
As the overall yield for dHA-1 synthesis was only 25 %, the synthesis protocol was optimized 
without further analysis of dHA-1. The obtained dHA-2 material showed an overall yield of 
79 %, but a low DoS of 1.25 %, corresponding to on average 3.4 azide groups per dHA 
molecule. Hence, further optimization of the synthetic protocol was performed and dHA-3 
was formed with an overall yield of 75 % and DoS of 2.53 %, corresponding to 6.94 azide 
groups per molecule (see sections 2.1.4 and 2.2.2).  
For similar materials derived from 200 kDa HA the degree of cross-linking after the 
cross-linking reaction can be determined by 1H-NMR analysis as described by Crescenzi et al. 
[81], calculating integrals for the aromatic triazole protons as well as acetylene protons of 
the N-acetylglucosamine present in the HA chain. The number of triazole protons directly 
represents the number of cross-links, as long as cross-linking is performed with azide- and 
alkyne-modified HA without bi-functional linker. Using bi-functional linker approaches 
single-sided linker reaction can introduce triazole protons without cross-links. Acetylene 
protons indicate the number of N-acetylglucosamine units, representing the number of 
Hyaluronan monomers and therefore the HA chain length. The resulting degree of 
cross-linking was reported to be 8 to 21 % [49, 81, 82, 86]. However, using 1H-NMR to 
determine the degree of cross-linking is limited by the low intensity of triazole peaks 
compared to acetylene signals and partial overlap of acetylene signals with other proton 
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signals. Furthermore, as HA is reported to have de-acetylated monomers [128-130], the HA 
chain length is underestimated by the 1H-NMR method.  Finally, the 1H-NMR method cannot 
distinguish between inter- and intramolecular cross-linking. Therefore the degree of 
cross-linking as determined by 1H-NMR has to be considered higher than the actual DoS. 
The method used to determine the DoS in this study is based on complete labelling of all 
accessible azide groups and removal of unbound dye. Unspecific binding of the dye to 
100 kDa HA was found to be as low as 0.04 dye molecules per HA chain. Potentially, the 
centrifugation step employed to remove free dye could lead to a loss in HA mass despite the 
fact that the mwco is tenfold lower than the HA MW, leading to an underestimation of the 
true DoS. A possible explanation for the lower DoS of the obtained dHA materials compared 
to literature values is the different HA quality used in literature. Nevertheless, a 2.5 mg/ml 
dHA-3 gel in PBS was chosen for further analysis and cross-linking. 
 
Fig. 3.1: SEC profile of dHA-3 (―) and 100 kDa HA (---). 
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The viscosity of 2.5 mg/ml dHA-3 as measured by mVROC analysis was 29.3 ± 2.4 mPas. 
2.5 mg/ml unmodified 100 kDa HA showed 27.6 ± 3.4 mPas. Hence, derivatization shows no 
effect on viscosity. At a concentration of 2.5 mg/ml dHA-3 solutions show easy handling and 
manual syringability through 20 G needles. 
To analyse MW and MW distribution of dHA-3 HPSEC analysis as well as centrifugation 
experiments were performed. Quantification of HA was performed using the modified 
carbazole method, although this method does not show good linearity and effects of HA 
derivatization, MW, and MW distribution are unclear.  
In HPSEC dHA-3 showed a broad peak from 8.2 to 9.4 ml as well as a small peak at 10 ml 
elution volume (Fig. 3.1). Unmodified 100 kDa HA showed a very broad peak from 8.5 to 
11.2 ml elution volume, reflecting a broad MW distribution. After centrifugation through a 
10 kDa mwco PES membrane 80.3 % of dHA-3 remained in the supernatant. For unmodified 
100 kDa HA 74.3 % were found. Using a 300 kDa mwco membrane 1.44 % of d-HA3 and 
1.56 % 100 kDa HA remained in the supernatant. Thus, esp. low MW HA molecules were lost 
during the derivatization and purification process of dHA-3 (overall yield: 74 %), but still a 
detectable low MW fraction remained. There is no indication for significant chain cleavage or 
unspecific cross-linking. The fact that a substantial fraction of 100 kDa HA passes the 10 kDa 
mwco membrane is due to the broad MW distribution of HA and the stretched shape of HA in 
PBS [33, 131, 132]. 
3.2. Preparation and characterization of cross-linked HA 
Cross-linking dHA should lead to a strong increase in MW. Therefore, HPSEC and 
centrifugation experiments were performed with 2.5 mg/ml cross-linked HA (cHA). As 
reference material 2.5 mg/ml 1.0 MDa HA was used. 
cHA showed a sharper SEC peak at approx. 9 ml elution volume (Fig. 3.2) compared to dHA-
3. Furthermore, a second peak at elution volumes of 7.0 to 7.9 ml and diffuse signals at high 
elution volumes were found. 1 MDa HA showed a broad peak from 7.9 to 9.7 ml elution 
volume, indicating a broad MW distribution. Centrifugation through 10 kDa mwco membrane 
left 88.4 % cHA and 100 % of 1 MDa HA in the supernatant. Using a 300 kDa mwco 
membrane 32.3 % of cHA and 46.9 % of 1 MDa HA were found in the supernatant.  
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Fig. 3.2: SEC profiles of cHA (―) and 1 MDa HA (...) 
This indicates the formation of cross-linked material with a higher MW in cHA compared to 
dHA-3. However, a large amount of unreacted dHA is still present. The reduced elution 
volume for the high MW fraction of cHA compared to 1 MDa HA is likely due to the changed 
three-dimensional structure of cross-linked material, limiting interaction with the SEC 
column. The increase in retention of cHA in centrifugation experiments compared to dHA-3 
is less pronounced than the difference between 1 MDa and 100 kDa uncroll-linked HA. 
Signals at high elution volume in cHA samples might be due to potential cleavage of dHA 
during the cross-linking reaction, as Cu-(II) and ascorbic acid, among other cross-linking 
reagents/catalysts, are reported to induce partial HA cleavage [133-135]. A simultaneous 
degradation would compete with cross-linking. Valachova et al. [134] report that 1 µM Cu-
(II) and 100 µM ascorbic acid lead to a significant reduction of viscosity for approx. 1 MDa HA 
within an hour – which is at lower concentrations and within shorter timeframe than applied 
for the cross-linking protocol employed in this study. Also Soltes et al. observe a decrease in 
viscosity for HA species > 800 kDa [135]. At the same time Crescenzi et al. and Testa et al. do 
not report any effects indicating HA cleavage [49, 54, 81, 82]. However, the reaction times 
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employed in these studies are far below one hour and the reaction was terminated by 
dialysis. Also the absolute amount of potential HA fragments found in SEC is apparently low. 
Hence, there is no prove for HA cleavage in CuAAC systems for 100 kDa or similar HA 
species. We conclude that HA chain cleavage is, if occurring at all during or after the cross-
linking reaction, a minor effect under the given circumstances. However, a cleavage of MW 
fractions above 800 kDa would be a significant limitation to the entire concept of 
cross-linking HA by CuAAC. Further studies would be required. The methods of choice to 
determine the MW distribution more precisely are mass spectrometry (for the low molecular 
weight fractions) or light scattering detectors (esp. for the high molecular weight fractions) 
on-line to SEC or AF4 systems [37, 136-138].  
Crescenzi and Testa described an increased viscosity for cross-linked HA materials [49, 81, 
82]. Compared to dHA-3 as well as unmodified 100 kDa HA, showing 29.3 ± 2.4 and 
27.6 ± 3.4 mPas, respectively, the viscosity of 2.5 mg/ml cHA remained unchanged: 
26.3 ± 2.8 mPas. The HA solutions remain free-flowing.  
The viscosity of HA samples increases strongly once a certain MW threshold is reached; likely 
approx. 360 kDa [41]. At the same time a strong concentration dependency is introduced. 
For smaller HA species viscosity values are less affected by MW and concentration changes.  
As SEC and centrifugation experiments show the increase in overall MW is only minor and 
obviously insufficient to increase viscosity. The increased viscosity observed by Crescenzi and 
Testa is likely due to the increased initial MW (200 kDa), being closer to the 360 kDa 
threshold, combined with a higher DoS leading to more effective cross-linking. 
The goal of this study is to develop in situ hardening hydrogel systems that can entrap and 
subsequently release protein pharmaceutics. However, there is no increase in viscosity by 
the cross-linking protocol employed. Furthermore, the formed material readily dissolved in 
water (visual inspection only). Thus, the cross-linked HA obtained during this study is 
inadequate for controlled release purposes and requires further optimization. 
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3.3. Protein stability during cross-linking reactions 
Some proteins, like e.g. hGH, HSA and Heme, are reported to be stabilized in presence of 
Cu2+ [139-141]. At the same time the Cu2+/ascorbic acid system is also reported to cleave 
several proteins [142]. This holds also true for the model IgG protein used in this study. 
Within 120 min incubation in 0.2 mM CuSO4 and 2.0 mM ascorbic acid, concentrations 
representing the cross-linking conditions described earlier, visible particles were formed. 
HPSEC showed a loss of monomer content of approx. 30 %. and formation of both 
aggregates and fragments after 120 min. Turbidity was increased from 0 to 1.2 FNU. 
Obviously, the Cu2+/ascorbic acid system leads to both aggregation and degradation of the 
antibody. Both are driven by metal induced oxidation [4, 143].  
However, successful click reactions (also including the Cu2+/ascorbic acid system) are 
reported for living systems [73, 144, 145] and in presence of protein [146-149]. For the IgG 
used in this study, even rather short time frames of ten minutes led to significant loss in 
protein integrity by Cu2+/ascorbic acid. We conclude that the stability of each protein has to 
be carefully evaluated. Cu-(I) based or, even more so, copper-free systems, are the most 
likely candidates to secure protein integrity.  
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4. Physico-chemical characterization of PMT gels 
4.1. Physico-chemical properties of H6P gels 
The first preliminary testing of PMT was performed with H6P which is derived from 
poloxamer 403 and hexamethyldiisocyanate (HDI) to form a 36 kDa polymer. The dry 
polymer formed white blocks with a semi-solid consistency and was readily soluble in water 
and PBS up to 25 %. At low temperatures (2-8 °C) clear solutions were formed. Upon heating 
to ambient temperature (≈ 20-22 °C) spontaneous clouding occured. Furthermore, viscosity 
increased and flowability was notably decreased. Heating to 37 °C, the white color remained 
and hardening continued. However, reaching 37 °C, the flowability increased again, 
indicating a loss in viscosity once a certain optimal temperature, which appears to be 
below 37 °C for H6P gels, was exceeded. Further increase in temperature led to continuous 
loss in viscosity and upon storage > 40 °C for one hour separation of an aqueous, 
transparent, low viscosity phase from the gel phase occurred. There was no visually 
detectable change in total sample volume within 2-45 °C. Manual injection via 20 G needle 
of a cooled (2-8 °C) 20 % gel into air as well as 37 °C warm PBS could easily be performed. 
Even at ambient temperatures, despite increased viscosity, manual injection through 20 G 
needle was possible. 
This overall profile is typical for poloxamer based thermo-responsive hydrogels [96, 114, 
115, 153]. From the mechanistic point of view this temperature profile represents the 
formation, interconnection and deformation of micelles as described by Mortensen et al. 
[92] and Walz et al. [96]. At low temperatures, the polymer is dissolved or assembled in a 
low number of micelles. With increasing temperature, more and more micelles form. When 
a certain micelle concentration and/or density is reached, clouding occurs. At even higher 
temperature and higher micelle concentration and density the hydrophilic PEO segments 
interconnect more strongly and rearrangement of micelles into lyotropic crystalline 
structures can occur. This interconnection and/or rearrangement leads to hardening [92, 
96]. Increasing the temperature even further induces loss of interconnectivity by 
micelle-deformation or matrix melting [92] and causes the gel strength to decrease. For H6P 
maximal gel strength appears to be reached below body temperature. The phase separation 
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observed for temperatures > 40 °C were also described by Ruel-Gariépy et al. and are caused 
by water exclusion upon further energetic optimization of the polymer matrix [87].  
Gel hardness and pore size depend on the density of polymer molecules and micelles. As 
summarized in [18], it can therefore be stated that usually drug release is sustained by 
increasing gel hardness [154, 155] as diffusion is slowed down by increasing gel density and 
hardness [116]. To analyse the hardening of thermo-responsive gels most studies use 
viscosimetric measurements [26, 28, 156]. In Fig 4.1 the rheological profile of 20 % H6P gel is 
shown. At approx. 10-25 °C both storage (G’) and loss modulus (G’’) were below 1 Pa, 
reflecting very low viscosity. These low viscosity values were maintained until approx. 25 °C, 
although visual and manual inspection indicated an earlier hardening onset at approx. 20 °C. 
At 25 °C a strong increase in both G’ and G’’, with G’ crossing G’’, was seen. Both G’ and G’’ 
showed maxima at approx. 40 °C, being 2100 Pa for G’ and 750 Pa for G’’. Again, visual and 
manual observations pointed to a lower temperatures of maximal viscosity below 37 °C. 
Above 40 °C both G’ and G’’ decreased, indicating gel melting as described in [92]. This loss 
in viscosity was not nearly as pronounced as noted visually and manually in that 
temperature range. Obviously, network formation/deformation was shifted to higher T 
(≈ 5 °C) in rheometry. Furthermore, the variability as indicated by the standard deviation is 
rather high. Likely both T shift and high variability are due to the shear forces employed, 
altering network structure.  
Therefore, penetration resistance analysis was established for further investigations. Similar 
tests to study mechanical properties of hydrogels were also reported in literature [157]. The 
penetration resistance profile of the H6P gel is in accordance to the manual and visual 
changes observed upon temperature increase (Fig. 4.2), showing < 1 mN at 21 °C, followed 
by a strong increase between 21 and 35 °C and subsequent decrease from 37 to 42 °C.  At 
35 °C, the temperature of maximal penetration resistance (Tmax) with approx. 120 mN was 
reached. Variability as indicated by standard deviation is much lower compared to the 
rheological measurements. 10 cycles of gel hardening and liquefying showed no significant 
(p = 0.05) impact on penetration resistance at 35 °C.  
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Fig 4.1: Storage ◆ (G’) and loss ◇ modulus (G’’) of 20 % H6P gels; n=3 
 
Fig. 4.2: Penetration resistance of 20 % gels of poloxamer 403 (■), poloxamer 407 (▲) and 
20 % H6P (●); n=3 
Drury et al. state that for tissue engineering adequate mechanical performance of a scaffold 
depends on specifying, characterizing, and controlling the material mechanical properties 
including elasticity, compressibility, viscoelastic behavior, tensile strength, and failure strain 
[158]. In muscle tissue approx. 20 N/cm², corresponding to 2.0 MPa, are generated [159]. 
Okay et al. report loss and storage moduli < 100 kPa for hydrogels [156]. Bromberg et al. 
report values < 1 kPa for a thermo-responsive gel [29]. These values correspond to moduli 
obtained for the 20 % H6P gel (see Fig. 4.4). Penetration resistance is determined with a 
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punch of 13.9 mm² square area. Thus, a penetration resistance of approx. 14 mN 
corresponds to a gel strength of 1.0 kPa and could be considered as the threshold for 
minimal gel strength. This threshold is reached by 20 % H6P gels between 27 and 42 °C. 
In contrast, a 20 % poloxamer 403 gel did not exhibit a relevant increase in penetration 
resistance up to 42 °C, while a 20 % poloxamer 407 gel showed continuous increase in 
penetration resistance from 21 to 39 °C, reaching a maximum of approx. 50 mN (Fig. 4.2). 
Thus, at body temperature penetration resistance of 20 % H6P gels more than doubles that 
of the 20 % poloxamer 407 gels. While 20 % poloxamer 403 und 407 gels dissolved quickly in 
PBS at 37 °C, inherently stable depots of 20 % H6P could be formed, although Tmax was 
exceeded. Fig. 4.3 shows such 20 % H6P depots, pre-formed as well as formed in situ via 
injection (20 G needle) at 37 °C. There was no visible degradation or swelling within 
four weeks in PBS at 37 °C followed by slow disintegration over several months (chapter 4.3).  
The described mechanical properties of 20 % H6P systems were not altered upon storage at 
2-8 °C for six months. Fulfilling these requirements, H6P is a promising candidate for more 
detailed studies, showing the desired thermo-reversible gelling profile and increased gel 
strength and reduced solubility at 37 °C compared to poloxamer 403 und 407 gels.  
 
Fig. 4.3: Depots derived from 20 % H6P gels in PBS at 37 °C; A: pre-formed, B: in situ-formed 
via injection (20 G needle) 
Like most thermo-responsive gels, the 20 % H6P gel exhibits a cloud point. The cloud point 
can be correlated with the lower critical solution temperature (LCST) of the gel [90, 160] as 
clouding is caused by a reduced transparency of the higher ordered structures formed at the 
LCST [87, 92, 96]. Thus, clouding and hardening depend on the LCST of the gel. This makes 
the cloud point as detected by UV spectroscopy [160] an interesting parameter for gel 
optimization. For 20 % H6P gels a cloud point of 25.2 °C was found (chapter 4.4). The first 
notable increase in turbidity was detected at approx. 20 °C, being in accordance with visual 
observations. 
A B 
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For initial release studies 20 mg/ml lysozyme or 150 kDa FITC-Dextran were dissolved in 20 % 
H6P gels. Depots were pre-formed and overlaid with 37 °C warm PBS and the released 
amount of model substance was monitored. For 150 kDa FITC-Dextran less than 20 % were 
released within the first 24 h, followed by complete release within 5 weeks (Fig. 4.4). 
Lysozyme was released faster with approx. 80 % within 24 h and 100 % after 48 h. Thus, for 
150 kDa FITC-Dextran the release is strongly delayed compared to literature data for 
unmodified poloxamer systems [17, 99]. In contrast to many hydrogel systems showing 
incomplete release [5, 24], 20 % H6P gels showed complete release of both lysozyme and 
150 kDa FITC-Dextran.  
As 20 % H6P gels exhibited both promising mechanical properties and sustained release of 
150 kDa FITC-Dextran, a series of PMT gels is investigated. The following chapters discuss 
temperature-sensitive gel strength, gel dissolution, cloud point and injectability of PMT 
systems. The aim was to identify candidates that offer adequate gel strength and erosion at 
body temperature. A sharp transition between sol and gel is preferred. Furthermore, the 
addition of protein should not negatively impact the gel forming process. Choosing 
candidates with the most promising physico-chemical properties, release and stability of an 
IgG antibody from/in PMT gels as well as PMT stability are investigated.  
 
Fig. 4.4: Cumulative release of 20 mg/ml 150 kDa FITC-Dextran (●) and 20 mg/ml lysozyme 
(■) from pre-formed 20 % H6P depots; n=3 
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4.2. Gel strength of PMT gels 
4.2.1. Effect of PMT molecular weight on gel strength 
For a series of HDI linked poloxamer 403 the impact of molecular weight on gel hardness was 
investigated. The range of 26 to 64 kDa, corresponding to four to eleven unimers, was 
analysed at 20 % gel concentration. A continuous increase in penetration resistance with 
increasing MW was observed (Fig. 4.5), reaching approx. 80 mN, 100 mN and 160 mN for the 
26 kDa, 43 kDa and 64 kDa polymer, respectively. At the same time the corresponding Tmax 
slightly decreased from 35 °C (26 and 36 kDa) to 33 °C (43 kDa) and 30 °C (48 and 64 kDa). 
Interestingly, the penetration resistance at 37 °C was nearly identical for the five polymers 
investigated. As all gels reveal satisfying penetration resistance of more than 14 mN they are 
candidates for further analysis. 
 
Figure 4.5: Penetration resistance of 20 % gels of HDI linked poloxamer 403 polymers with  
26 kDa (H4P, ■), 36 kDa (H6P, ●), 43 kDa (H7P,▲), 48 kDa (H8P,▼) and 64 kDa (H11P, ◆); 
n=3 
An increase in gel hardness with increased MW is known for various gel systems [27, 29, 154]. 
As gel formation in poloxamer systems is caused by micelle formation and packing [92, 94], 
gel strength is mainly driven by interactions between PEO chains of adjacent micelles [161]. 
With increasing MW and, correspondingly, the number of poloxamer and PEO unimers, the 
range of this interaction is either expanded over two or more micelles, or intensified 
between directly adjacent micelles. This leads to increased gel hardness. This is in 
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accordance with results by Cohn et al.  who found that the viscosity of poloxamer 407 
oligomer gels increases with the oligomer chain length [112]. 
Alexandridis et al.. found that for a given PPO to PEO ratio, poloxamers of higher molecular 
weight form micelles more readily, i.e. at lower concentrations and temperatures [162] as 
the free energy change for the transfer of one mole of poloxamer from solution to the 
micellar phase increases [163]. Considering PMTs as high molecular weight poloxamers, and 
knowing that  micelle concentration is an important trigger to gel hardening [92], this effect 
can be seen for the MW series investigated: the higher the MW the lower Tmax. Also for 
poloxamer 407 gels Tmax decreased with higher number of poloxamer unimers in a chain-
elongated system [112].  
As the hardness at the in vivo release temperature of 37 °C is similar for the polymers of 
different MW investigated, differences in release profiles at 37 °C should be minor [116, 118, 
154, 155]. However, the lower Tmax at high MW may counteract easy handling and 
syringeability and lower MW PMTs with high Tmax may be favourable.  
4.2.2. Effect of PMT concentration on gel strength 
Subsequently, a concentration series of H6P gels was analysed. A strong impact of polymer 
concentration on penetration resistance is seen (Fig. 4.6). At 10, 15, 20 and 25 % the 
maximal penetration resistance was approx. 20, 60, 120 and 140 mN, respectively. At 25 % 
H6P the Tmax was 31 °C, for the other concentrations approx. 35 °C. At 37 °C 20 % and 25 % 
H6P result in the same penetration resistance of approx. 100 mN. For 15 % and 10 % the 
mechanical strength at 37 °C was reduced to approx. 60 and 20 mN, respectively. All values 
were above the 14 mN threshold and all concentrations could be considered as possible 
candidates for further analysis. 
An increase in gel hardness due to an increase in gel concentration is known for most gel 
systems [27, 29, 154]. At high concentrations the effect diminishes and the 20 % and 25 % 
H6P gels show very similar penetration resistance at 37 °C. The increased gel strength is 
caused by an overall increase in micelle concentration and, thus, density, or by an increased 
micelle size as found by Cohn et al.. for similar chain-elongated poloxamer systems [112]. 
Also the shift in Tmax corresponds to the micelle-packing mechanism [92, 94], as for 
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increasing poloxamer 403 concentration the transition temperatures from micelle solutions 
to mechanically more stable liquid crystalline states decreases [100]. 
 
Figure 4.6: Penetration resistance of 10 (■), 15 (●), 20 (▲) and 25 (▼) % gels of 36 kDa H6P; 
n=3 
A concentration of 20 % PMT appears to be optimal. Lower concentrations could lead to 
faster drug release as the hardness, i.e. mesh density, is decreased [154]. A higher 
concentration may hinder injectability. This ideal concentration is 10 % lower than found by 
Cohn et al.. for similar poloxamer derivatives [112]. Other environmentally-sensitive 
hydrogel systems require similar to higher concentrations as well, e.g. > 20 % for PEO-PLA 
[164], > 30 % for poloxamer-cellulose derivatives [165] or > 25 % for pNiPAAm systems [166].  
4.2.3. Effect of diisocyanate linker on gel strength 
Three different diisocyanates were used to obtain polymers of similar MW: BDI, MDI and HDI. 
The impact of the diisocyanate linker on the penetration resistance was investigated at 20 % 
gel concentration (Fig. 4.7). It was found that M6P gels, cross-linked with MDI, had a lower 
overall penetration resistance than H6P gels, cross-linked with HDI, showing approx. 90 mN 
compared to 120 mN at the corresponding Tmax of approx. 33 °C and 35 °C, respectively. 20 % 
B7P gels, cross-linked with BDI, showed the same maximal penetration resistance as 20 % 
H7P gels of approx. 125 mN. However, for 20 % B7P gels Tmax was shifted to approx. 38 °C 
and, thus, the hardness at 37 °C was markedly increased.  
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Figure 4.7: Penetration resistance of 20 % H6P (●), M6P (■), H7P (▲) and B7P (▼) gels; n=3 
All three diisocyanates act as lipophilic linkers, and lipohilic linker lengths increases from BDI 
to HDI and MDI. However, the linker size is small compared to the poloxamer building blocks 
with approx. 5800 Da for each poloxamer 403 unimer. As gel formation is caused by 
interpenetration of micelles by the PEO segments [94], introducing a lipophilic moiety next 
to this anchor might reduce gel strength. This could explain why polymers linked with the 
most lipophilic linker, MDI, render softer gels than HDI linked polymers, while gels from BDI 
linked polymers show highest penetration resistance. The difference between HDI and BDI is 
only minor, as the difference in lipophilicity is small.  
Less lipophilic poloxamers require higher temperatures to form ordered structures, as their 
critical micellation temperature (CMT) is increased [162, 163, 167]. This probably causes the 
increased Tmax for BDI linked polymer gels compared to HDI and MDI linked polymer gels. 
Due to the higher gel strength at 37 °C, B7P might lead to an enhanced sustained release 
effect in vivo compared to polymers linked with HDI or MDI. However, penetration 
resistance remained > 14 mN for all three differently linked polymer gels, making any of 
these PMTs potential candidates for further analysis. 
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4.2.4. Impact of the poloxamer type on gel strength 
The PMTs consist of either poloxamer 403, 407, 308 or defined mixtures of them. Poloxamer 
403 has a lower PEO content (30 %) than 308 (80 %) or 407 (70 %) and is thus more 
lipophilic. At the same time poloxamer 308 and 407 have markedly higher molecular weights 
compared to 403 (14.6 and 12.6, respectively, vs. 5.8 kDa). Thus, at the similar final MW of 
the PMT the number of poloxamer unimers differs strongly. To analyse the effect of the 
poloxamer type on gel hardness the penetration resistance profiles of five different PMTs 
with increasing PEO to PPO ratio at 20 % were measured (Fig. 4.8). The PMTs chosen were 
H8P (48 kDa, PEO:PPO 3:7), H5P2F (51 kDa, PEO:PPO 3:4), H2.5P2.5F (48 kDa, PEO:PPO 1:1), 
H1.5P1.5F1.5f (49 kDa, PEO:PPO 3:2) and H4F (55 kDa, PEO:PPO 7:3). They have a similar MW 
of approx. 50 kDa and increasing hydrophilicity in the above mentioned order due to 
PEO:PPO ratios of 3:7, 3:4, 1:1, 3:2 and 7:3, respectively. The PEO chain length of the 
underlying poloxamer qualities are 20 units for poloxamer 403, 100 units for poloxamer 407 
und 133 units for poloxamer 308. Interestingly, at the entire temperature range investigated 
H4F gels were almost transparent, in contrast to all other gels which exhibited slight 
turbidity. 
 
Figure 4.8: Penetration resistance of 20 % H8P (■), H5P2F (●), H2.5P2.5F (▲), 
H1.5P1.5F1.5f (▼) and H4F (◆) gels; n=3 
It was found that an increased PEO:PPO ratio led to a strong increase in penetration 
resistance compared to H8P with approx. 100 mN at a Tmax of 33 °C. H5P2F gels showed 
approx. 700 mN gel strength at Tmax of 39 °C. For gels with even higher PEO:PPO ratio Tmax 
could not be detected as it was shifted to temperatures > 42 °C and a continuous increase in 
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penetration resistance was found between 21 and 42 °C. At 42 °C 20 % gels of H2.5P2.5F, 
H1.5P1.5F1.5f and H4F presented a gel strength of approx. 850 mN, 500 mN and 600 mN, 
respectively. Also at 21 and 24 °C H5P2F, H2.5P2.5F and H4F gels showed increased gel 
strength compared to H8P gels. For H1.5P1.5F1.5f gels the increased gel strength was 
detected from 30 to 42 °C compared to H8P gels. Also at low temperatures (2-8 °C) PMT gels 
with increased PEO:PPO ratio showed markedly increased viscosity (manual inspection only). 
This increased gel strength at low temperatures could compete with syringeability.  
Increased gel strength of PMTs with increased PEO content and/or longer PEO chains is 
caused by their increased physical polymer cross-linking capacity [92, 94] and was  also 
found by Cohn et al.. for similar chain-elongated poloxamers [112]. The increase in Tmax with 
increasing PEO:PPO ratio is caused by the increased CMT of more hydrophilic polymers [162, 
163, 167], increasing the temperature required to form (interconnected) PMT micelles.  
As the penetration resistance values at 37 °C vary strongly, differences in release profiles at 
this temperature are expected [116, 154, 155]. However, Moore et al. reported that release 
from poloxamer 407 systems is mainly caused by fast erosion/solution of the gel, not 
diffusion [168]. Therefore, the dissolution of gels based the more hydrophilic PMTs has to be 
evaluated critically (chapter 4.3.4) In general more hydrophobic gels show more pronounced 
sustained release than more hydrophilic matrices [154]. Overall, despite their high 
mechanical strength, poloxamer 407 and 308 based PMTs are expected to show faster 
protein release than poloxamer 403 based systems. In addition, the impact of the increased 
gel strength at low temperatures on syringeability has to be evaluated.  
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4.2.5. Effect of the addition of PEO and PPO on gel strength  
As seen for PMTs based on different poloxamer qualities and elongated with different 
diisocyanates, hydrophilicity plays an important role in gel hardening affecting both maximal 
gel strength and Tmax. Hence, addition of hydrophilic or lipophilic molecules like PEO or PPO 
could be an option to influence gel formation. Consequently, 5 % PEO and PPO of different 
MW were added to 20 % H8P and the penetration resistance was characterized. 
 
Figure 4.9: Penetration resistance of 20 % H8P (◐) gels with additional 5 % PEO 1kDa (■), PEO 
4 kDa (▲), PEO 20 kDa (▼),  PPO 2 kDa (□) or PPO 4 kDa (△); n=3 
Addition of PEO leads to a shift in Tmax to lower temperatures and reduced overall 
penetration resistance compared to 20 % H8P gels without additive (Fig. 4.9). With 
increasing PEO MW from 1 to 4 and 20 kDa this effects becomes more pronounced. The non-
covalently bound PEO appears to reduce the binding strength of the poloxamer PEO units 
within the micelle-network, as it can compete for binding sites. The decrease in Tmax can be 
explained by interactions between the PEO blocks of poloxamer unimers and the free PEO. 
This additional interaction leads to a more favorable micelles formation at lower 
temperature and, hence, a reduction of CMT [87]. The reduced gel strength at 37 °C will 
likely lead to increased release rates of PEG loaded gels compared to 20 % H8P gels without 
additive, and an increase in gel strength at low (2-8 °C) and ambient temperature is likely to 
compete with syringeability. Adding 5 % PPO strongly reduces the overall penetration 
resistance strongly. As seen before, more lipophilic PMT gels lead to softer gels as 
lipophilicity competes with PEO interactions, the main driving force of gel formation. 
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Thus, both PEO and PPO addition leads to a decrease in gel hardness at 37 °C and may lead 
to a faster drug release. For a PMT which would show a Tmax significantly above 37 °C, 
addition of free PEO could be used to adapt Tmax. PEO might also show positive effects on 
protein stability, while the lipophilic PPO might destabilize proteins [4]. Therefore, PMTs 
with PPO additives are excluded from further experiments.  
4.2.6. Influence of protein load on gel strength 
Incorporation of any drug can influence the mechanical properties of gels, as it introduces 
polymer-drug and drug-solvent interactions [18, 169]. Therefore, the penetration resistance 
of a set of protein loaded gels was analysed. These were 20 % H6P gels with 80 mg/ml IgG, 
20 % H8P gels with 50 mg/ml Lysozyme and 20 % H6F gels with 20 mg/ml IgG (Fig. 4.10). 
For 20 % H6P and 20 % H8P gels 80 mg/ml IgG (Fig. 4.10A) and 50 mg/ml Lysozyme 
(Fig. 4.10B), respectively, had no effect on the penetration resistance at 37 °C. Overall gel 
hardness was reduced, but simultaneously Tmax increased to approx. 37 °C. The hydrophilic 
proteins may compete for binding sites in the shell of PMT micelles leading to decreased 
interconnectivity and, thus, reduced mechanical strength. Furthermore, the reduced 
penetration resistance could be caused by steric hindrance of micelle interaction by the 
large protein molecules. Both effects may also explain the increased Tmax. As gel strength is 
expected to strongly influence drug release protein loaded 20 % H6P and H8P gels with Tmax 
values close to 37 °C may be especially promising matrices for sustained protein release. 
For 20 % H6F gels with 20 mg/ml IgG (Fig. 4.10C) the onset of hardening was shifted to 
approx. 33 °C compared to approx. 28 °C for the protein free gel, followed by the strong 
increase in gel hardness for the PEO rich PMT gel. Thus, for the protein loaded gel the 
penetration resistance at 37 °C was reduced to 650 mN compared to 800 mN found for the 
protein free gel. The reduced gel strength and increased temperature required to induce gel 
hardening may be explained by protein molecules competing for PEO binding sites and 
sterically hindering micelle formation and interconnection. Despite the high gel strength at 
37 °C of 20 % H6F gels with 20 mg/ml IgG a fast gel dissolution as seen for all PEO rich PMT 
gels is expected, which should lead to a fast protein release. 
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Figure 4.10: Penetration resistance of A: 20 % H6P gels (■) with 80 mg/ml IgG (●); B: 20 % 
H8P gels (■) with 50 mg/ml Lysozyme (●); C: 20 % H6F gels (■) with 20 mg/ml IgG (●); n=3 
20 25 30 35 40 45
0
20
40
60
80
100
120
140
160
P
e
n
e
tr
a
ti
o
n
 r
e
s
is
ta
n
c
e
 [
m
N
]
Temperature [°C]
20 25 30 35 40 45
0
20
40
60
80
100
120
140
160
P
e
n
e
tr
a
ti
o
n
 r
e
s
is
ta
n
c
e
 [
m
N
]
Temperature [°C]
20 25 30 35 40 45
0
200
400
600
800
1000
1200
P
e
n
e
tr
a
ti
o
n
 r
e
s
is
ta
n
c
e
 [
m
N
]
Temperature [°C]
A 
B 
C 
 
42 
4.3. Dissolution of PMT depots 
Unmodified poloxamer gels are known to dissolve in physiological media within a few days 
[17, 98]. Therefore, release is mainly governed by depot erosion [168] and completed within 
hours to days [17, 98]. To overcome this short release period, PMTs are designed to show 
decreased solubility and to enable a better release control by matrix diffusion [118, 155]. At 
the same time, dissolution of the polymer matrix is a key parameter. Hence, dissolution 
rates of different PMT depots were investigated. PMT gels based on a MW series of HDI 
linked poloxamer 403, a concentration series of H6P, PMTs formed by different 
diisocyanates and from different poloxamer qualities, as well as PMT gels with PEO or 
protein were pre-formed at 37 °C and overlaid with 37 °C warm PBS. Furthermore, H6P 
depots were pre-formed and processed at different temperatures (32, 35, 39 or 42 °C) or 
were in situ-formed by injection of cooled (2-8 °C) gel into 37 °C warm PBS. Depot erosion 
was monitored visually on a daily basis for 4 days and on weekly base for another 12 weeks 
and can be caused by either hydrolysis of the urethane linkers and/or dissolution of the 
polymer molecules in the surrounding medium. 
4.3.1. Effect of PMT molecular weight on dissolution of PMT depots 
As shown in table 4.1 dissolution time increased with increasing PMT MW. While unmodified 
poloxamer 403 was completely dissolved within 4 days, the smallest PMT, H4P with 26 kDa, 
required approx. 10 weeks. PMTs with even higher MW showed only incomplete or no 
dissolution within 88 days. For 36 and 48 kDa PMT depot disintegration and subsequent 
particle dissolution was observed. These dissolving particles, as well as depots of unmodified 
poloxamer 403 and H4P, showed a loss in turbidity shortly prior to complete dissolution. At 
this time point polymer concentration within the depot or particle is too low to maintain 
clouding. The decreased dissolution rate of high MW 20 % PMT gels based on poloxamer 403 
and HDI is in contrast to the identical gel strength at 37 °C observed for a MW series of these 
PMT gels. This can be explained by reducing polymer solubility with increasing MW. 
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Tab. 4.1: Dissolution of pre-formed 20 % gels of poloxamer 403 and a MW series of 
poloxamer 403 chain-elongated with HDI; 37 °C; n=1  
4.3.2. Effect of gel concentration on dissolution of PMT depots 
PMT concentration was found to affect the dissolution time (table 4.2). At 37 °C pre-formed 
10 % H6P depots showed first signs of erosion after 32 days, and complete dissolution after 
81 days. These gels became transparent after day 74. For 15 % gels it took 46 days until first 
visible erosion – complete dissolution was not reached within the monitored period of time. 
20 % H6P showed first visible dissolution after 60 days that was not completed after 88 days. 
Increasing the PMT concentration to 25 % did not affect the disintegration behavior any 
further. For 15 and 20 % gels formation of single smaller particles was observed. These 
became transparent and dissolved after 14 days each.  
 
Tab. 4.2: Dissolution profiles of 10, 15, 20 and 25 % pre-formed H6P (36 kDa) depots at 
37 °C; n=1  
The dissolution profiles correlate with gel strengths at 37 °C as the soft 10 % gel dissolves the 
fastest, while harder gels take more time to dissolve. Differences in both penetration 
resistance at 37 °C and dissolution at 37 °C between 20 and 25 % H6P gels are only minor. 
The loss in turbidity shortly to complete dissolution of particles found in 15 and 20 % 
samples as well as of the entire 10 % gel indicate a continuous loss in polymer concentration 
to values below the cloud point. 
  
Polymer name
Poloxamer 
403
H4P H6P H7P H8P H11P
Polymer Mw [kDa] 5.8 26 36 43 48 64
Time point of first 
visible erosion [d]
< 1 25 60 74 74 > 88
Completely 
dissolved after [d]
4 67 > 88 > 88 > 88 > 88
PMT concentration 
[% w/w]
10 15 20 25
Time point of first 
visible erosion [d]
32 46 60 60
Completely 
dissolved after [d]
81 > 88 > 88 > 88
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4.3.3. Effect of the diisocyanates on dissolution of PMT depots 
Comparing H6P (36 kDa) with M6P (37 kDa) as well as H7P (43 kDa) with B7P (42 kDa) at 
20 % gel concentration a strong influence of the employed diisocyanate linker on dissolution 
rate of pre-formed depots at 37 °C was found (table 4.3). B7P showed no signs of erosion 
within 88 days. As already mentioned for H6P and H7P gels first erosion effects were found 
after 60 and 74 days, respectively. Neither of them was completely dissolved within 88 days. 
In contrast, for M6P gels erosion became first visible by a reduction in gel volume after 
18 days, and dissolution was completed after 39 days. Again, opalescence was lost just prior 
to complete dissolution. Hence, the BDI linked PMT showed the slowest dissolution rate, HDI 
linked PMTs had intermediate rates, and MDI linked PMT gels dissolved the fastest. This 
order is in accordance with the penetration resistance (see section 4.2.3): the softer M6P 
gels dissolves faster, the harder B7P slower than the corresponding H6P and H7P gels. Likely, 
a reduced interconnectivity of micelles leads to faster dissolution and softer gels. 
 
Tab. 4.3: Dissolution of pre-formed 20 % PMT depots derived from H6P (36 kDa), H7P 
(43 kDa), B7P (42 kDa) and M6P (37 kDa) at 37 °C; n=1 
4.3.4. Effect of the poloxamer type on dissolution of PMT depots 
Variation in the PEO:PPO ratio due to the use of different poloxamer unimers in PMT 
synthesis were found to strongly affect dissolution rates (table 4.4). 20 % gels of H8P 
(48 kDa, PEO:PPO ratio of 3:7) showed first signs of erosion after 74 days, but were not 
completely dissolved within 88 days. In contrast, 20 % H5P2F (51 kDa, PEO:PPO ratio of 3:4) 
gels started to lose volume immediately after PBS was added and dissolution was completed 
within 4 days. Gels containing 20 % H2.5P2.5F (48 kDa, PEO:PPO ratio of 1:1) or H4F (55 kDa, 
PEO:PPO ratio of 7:3) showed an even faster dissolution completed within 2 days. 
Unmodified poloxamer 407 (12.6 kDa) showed very similar dissolution rates as H4F. 20 % 
poloxamer 407 gels and 20 % H4F gels became almost transparent when PBS was added, 
Linking 
diisocyanate
HDI BDI H12MDI
Time point of first 
visible erosion [d]
60 / 74 > 88 18
Completely 
dissolved after [d]
> 88 / > 88 > 88 39
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while 20 % H5P2F and H2.5P2.5F gels became transparent shortly prior to complete 
dissolution. H8P gels remained turbid throughout the entire timeframe investigated.  
Obviously, despite their increased gel strength, the more hydrophilic PMT gels containing 
poloxamer 407 dissolve faster than PMT gels containing only poloxamer 403. This is in good 
accordance to [162, 163, 167]: more hydrophilic poloxamer systems form less stable 
micelles. Although Cohn et al. [112, 114] found that a 30 % gel of a poloxamer 407 tetramer 
linked with HDI (being nearly identical to H4F as used in this study) sustained in vitro peptide 
release at 37 °C for several weeks, the PEO rich PMTs H4F, H5P2F  and H2.5P2.5F are no 
candidates for further analysis due to their fast dissolution rate.  
 
Tab. 4.4: Dissolution of pre-formed 20 % depots at 37 °C. PEO:PPO ratios represent 48 kDa 
H8P (3:7), 51 kDa H5P2F (3:4), 48 kDa H2.5P2.5F (1:1), 55 kDa H4F (7:3) and 12.6 kDa 
unmodified poloxamer 407 (7:3); n=1 
4.3.5. Effect of PEO addition on dissolution of PMT depots 
In section 4.3.5 addition of PEG to PMT gels was discussed as potential method to adjust gel 
strength and Tmax: at 37 °C gel strength was decreased by addition of PEG, being more 
pronounced the higher the PEG MW. Analogously, addition of 5 % PEG (1 and 20 kDa) to 20 % 
H8P gels lead to faster dissolution rate at 37 °C compared to pure H8P systems. For 1 kDa 
PEG the gel disintegrated into small particles after 4 days and dissolved completely within 
46 days. Addition of 20 kDa PEG lead to immediate dissolution into small particles after 
addition of PBS and complete dissolution within 3 days.  
By addition of PEG the micellar network formed by PMTs becomes less dense and less 
coherent due to a reduced intermicellar interaction. As PEG could be released from the PMT 
gel over time, matrix healing with newly introduced interconnection of micelles can occur 
afterwards. For 1 kDa PEG this matrix healing might explain the long timeframe between 
first visible sign of dissolution and complete dissolution. Thus, small amounts of low MW PEG 
might offer a way to accelerate matrix dissolution of PMT gels. For 20 kDa PEG the 
interference with the gel network is too strong and its addition is not a valuable approach. 
PEO:PPO ratio 3:7 3:4 1:1 7:3
Time point of first 
visible erosion [d]
74 < 1 < 1 < 1 / < 1
Completely 
dissolved after [d]
> 88 4 2 2 / 3
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4.3.6. Effect of protein load on dissolution of PMT depots 
In section 4.3.6 addition of IgG to 20 % H6P gels was shown to shift Tmax to higher 
temperatures and reducing the maximal gel strength; at 37 °C both effects canceled each 
other out, leading to nearly identical gel strength as for protein free gels. Consequently, 
addition of 20 or 80 mg/ml to 20 % H6P depots had only minor effects on dissolution rates. 
Without protein, H6P depots took 60 days to show first visible erosion. At 20 mg/ml IgG this 
time frame was slightly increased to 67 days, but remained 60 days at 80 mg/ml. In each 
case, erosion was mainly characterized by loss in total volume. Independent of IgG 
concentration, 20 % H6P gels were not completely dissolved within 88 days. As for addition 
of PEG, release of IgG from the micellar/gel network might result in identical structures 
formed in absence of protein. Thus, dissolution rates should become identical to protein free 
gels once the entire IgG was released. 
4.3.7. Effect of temperature on dissolution of PMT depots 
Since PMT gels show thermo-reversible hardening, an impact of temperature on dissolution 
was to be expected. As shown in table 4.5 at 32 °C the onset of erosion of 20 % H6P gels was 
seen after 46 days, but the gel was not completely dissolved after 88 days. At 35 °C no visible 
erosion within the investigated time frame occurred at all. For 37 °C and 39 °C the starting 
erosion was found after 60 and 39 days, respectively, but still gel dissolution was not 
completed within 88 days. At 42 °C disintegration into numerous small particles occurred 
after 2 days and these particles became entirely dissolved after 11 days. Near body 
temperature gels offer sufficient stability to become potential depots for controlled drug 
release. 
 
Tab. 4.5: Dissolution profiles of pre-formed 20 % H6P depots at varying temperatures; n=1 
  
Temperature [°C] 32 35 37 39 42
Time point of first 
visible erosion [d]
46 > 88 60 39 2
Completely 
dissolved after [d]
> 88 > 88 > 88 > 88 11
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The closer to Tmax, the harder 20 % H6P gels gels become and the slower they dissolve; this 
correlation between hardening profile and dissolution rate is another proof that increased 
interconnectivity of micelles reduces dissolution rates. The change in erosion profile from 
loss in volume by near Tmax to complete disintegration into particles at 42 °C is in good 
accordance to the melting of micellar matrices as described in [92]. 
4.3.8. Dissolution of pre-formed and in situ-formed PMT depots 
The aim of this thesis is to develop in situ forming, injectable smart hydrogels for controlled 
protein delivery. Comparing dissolution behavior of pre-formed and in situ-formed 20 % H6P 
depots no difference could be seen, although gels were of markedly different shape (see Fig. 
4.5). As also gel strength at 37 °C was very similar, matrix formation in injected PMT gels 
appears to be fast enough to form controlled release depots in situ.  
4.4. Cloud point of PMT solutions and gels 
All 20 % PMT gels except H4F and H6F become turbid when exposed to ambient or body 
temperature; H4F and H6F are turbid in the entire temperature range investigated. 
However, turbidity is notably less for H4F and H6F gels compared to poloxamer 403 based 
PMTs. Clouding in poloxamer based systems is caused by an increase in micelle 
concentration (at constant micelle size), leading to strongly pronounced light scattering [161, 
167, 170]. The temperature required for clouding is called cloud point (cp) and usually 
defined as the infliction point of temperature-turbidity or temperature-transmittance graphs 
[171]. Micelle formation shows a concentration threshold, the critical micellation 
concentration (CMC), and a temperature threshold, the critical micellation temperature 
(CMT). As clouding of poloxamer based polymer solutions requires micelles, it can be stated 
that CMT ≤ cp and effects decreasing CMT should also decrease cp. Furthermore, in chapter 
4.2 it could be shown that changes in CMT also shift the Tmax of gel strength.  
In situ-formation of PMT gels requires a fast temperature shift; ideally from temperatures 
that offer low viscosity (< CMT) to temperatures close to Tmax, where the highest gel 
strength, representing strong micelle interconnectivity, is reached. The closer CMT is to Tmax, 
the lower the required heat transfer becomes and the faster and more reproducible gel 
formation should be. To choose the ideal PMT for controlled protein release from in 
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situ-formed depots, a CMT close to Tmax is desired; and cp values are considered an indirect 
measure for CMT. 
Since at relevant gel concentration most PMT systems investigated reached turbidity values 
above the detection limit of the applied photometer, infliction points cannot be determined 
directly. Therefore, in this study, cp is defined as approximately identical to the temperature 
with absorbance > 2.0. As mostly the increase in turbidity is very sharp, the differences 
between this estimated value and the true infliction point should be minor.  
4.4.1. PMT molecular weight effect on cp 
Fig. 4.11 shows temperature-absorbance graphs of 20 % gels of H4P (26 kDa), H6P (36 kDa), 
H7P (43 kDa) and H11P (64 kDa). Overall, the absorbance increase correlates well with the 
visual observation of a strong increase in turbidity close to ambient temperatures. 
Calculated cp values were 25.4, 25.2, 23.3 and 22.4 °C for 26 (H4P), 36 (H7P), 43 (H7P) and 
64 kDa (H11P), respectively. Hence, cp decreases with increasing MW, representing a 
decreasing CMT.  
As discussed in chapter 4.2.1 increasing MW leads to decreasing Tmax. Independent of PMT 
MW cp appears to be approx. 10 °C lower than Tmax. Therefore, the difference between CMT 
and Tmax can be considered identical for all MW investigated.  
 
Fig. 4.11: Temperature-absorbance profiles of a H4P (26 kDa,■), H6P (36 kDa,●), H7P 
(43 kDa,▲) and H11P (64 kDa,◆); to maintain legibility only every forth data point collected 
is indicated; n=2 
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4.4.2. PMT concentration effect on cp 
No direct correlation between gel concentration and cp can be seen (Fig. 4.12). Only at the 
very low concentration of 0.1 % H6P a continuous increase in absorbance was found. For all 
other concentrations a sharp increase in absorbance at ambient temperatures could be 
seen. Cp values were 42.8, 23.2, 23.1, 23.2, 24.5 and 25.2 °C for 0.1, 1.0, 5.0, 10, 15 and 20 % 
samples, respectively. Concentrations of 1.0, 5.0 and 10 % lead to nearly identical cp values, 
approx. 1-2 °C lower than for 15 and 20 % gels. As shown in chapter 4.2.2 Tmax is decreasing 
with increasing gel concentration. Although the observed differences are small, it can be 
stated that for 20 % gels the difference between cp and Tmax is smaller than for the other gel 
concentrations investigated. 
 .  
Fig. 4.12: Temperature-absorbance profiles of 0.1 (□), 1.0 (○), 5.0 (△), 10 (▽), 15 (●) and 
20 % (■) 36 kDa H6P gels; to maintain legibility only every forth data point collected is 
indicated; n=2 
4.4.3. Effect of diisocyanate structure on cp 
As Fig. 4.13 shows absorbance profiles and cp depend strongly on diisocyanate quality. 20 % 
M6P gels revealed a cp of 20.9 °C, whereas the gels prepared from H6P with corresponding 
MW exhibited a cp at 25.2 °C. A similar trend is seen for B7P (42 kDa) vs. H7P (43 kDa): The cp 
values were 27.3 °C for 20 % B7P and  23.3 °C for 20 % H7P, respectively. Interestingly, M6P 
showed a lag in absorbance increase close to cp.  
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Fig. 4.13: Temperature-absorbance profiles of 20 % M6P (●), H6P (■), H7P (▲) and B7P (▼); 
to maintain legibility only every forth data point collected is indicated; n=2 
These results correspond to penetration resistance measurements. Compared to HDI based 
PMTs  the more lipophilic MDI induces a slight Tmax shift to lower temperatures, while the 
less lipophilic BDI gels show a markedly increased Tmax. The lag close to cp for the M6P graph 
is another hint that either micelle formation is not as linear as expected, or turbidity 
depends on more processes but micelle formation. Regardless of this effect, M6P shows a 
reduced cp but rather similar Tmax compared to H6P. Thus, the gel network formation 
requires a stronger temperature shift for M6P gels than for H6P gels and H6P is beneficial in 
terms of fast sol-gel transition. B7P has increased Tmax and increased cp compared to H7P, 
reflecting similar temperatures shifts required for in situ-hardening and, thus, BDI and HDI 
based poloxamers can be considered similar in terms of the sol-gel transition. 
4.5. Injectability of PMT gels 
As discussed in chapter 4.1 cooled (2-8 °C) 20 % H6P gels are easily injectable with 20 G 
needles as shown by manual observation. Additionally, gels at ambient temperature were 
tested for injectability with 20 G needles at 100 µl/sec (Fig. 4.14). For PBS a constant 
injection force of approx. 3 N was neccessary. 10 and 15 % H6P gels revealed an increase in 
injection force required within the first 50 µl. Subsequently, a plateau at approx. 8 N was 
reached. At 20 % gel concentration a continuous increase in injection force for more than 
200 µl was seen, reaching peak force of approx. 25 N followed by a decrease to 20 N at high 
standard deviation. 
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Fig. 4.14: Injection force measurements of PBS (■), 10 (▲), 15 (▼) and 20 % (●) H6P using a 
1 ml syringe with 20 G needle at ambient temperature with 100 µl/sec; n=3 
For PLGA systems similar forces of 20 N and more are reported for injection into air and a 
meat model at approx 30 µl/sec [172]. Furthermore, injection forces of up to 25 N are found 
to correlate with “easy” injection in vivo [172]. Cilurzo et al. report that injection forces of 
approx. 14 N “went smooth”  [173]. Hence, all H6P gels discussed above can be classified as 
easily syringeable or syringeable using 20 G needles at ambient temperatures.  
However, to limit the pain for subcutaneous or intramuscular injection 22 to 25 G or even 
smaller needles are most common [174]. 20 G needles have an inner diameter of approx. 
0.6 mm and an outer diameter of approx. 0.9 mm, whereas e.g. 22 G needles have 0.4 and 
0.7 mm, respectively. Injection forces increase with decreasing needle size [174] and 
increasing injection speed [172]. Thus, to use smaller needles for PMT gel injection, two 
options are available: (i) reducing the injection speed; (ii) injecting cooled gel with its 
decreased gel viscosity. Further studies could reveal the ideal compromise between injection 
volume, injection speed, injection depth, gel concentration, gel temperature and needle size. 
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As shown in Fig. 4.15 for 20 % PMT gels at ambient temperature the injection force required 
increases with increasing MW as Tmax is shifted closer to ambient temperatures (chapter 
4.2.1). 26 kDa H4P reached a plateau of approx. 15 N after 100 µl. For 36 kDa H6P a peak of 
26 N was found after 250 µl, followed by a plateau at 20 N. At 43 kDa (H7P) the peak force of 
42 N was reached at 320 µl, followed by a decrease to approx. 30 N. 64 kDa H11P gels 
exceeded the upper detection limit of the system (60 N) immediately after measurement 
start. Thus, 20 % H6P and H7P gels can be classified as injectable, 20 % H4P gels as easily 
injectable [172]  at the applied conditions, whereas 20 % H11P gels are not injectable. 
 
Fig. 4.15: Injection force measurements of 20 % H4P (26 kDa, ■), H6P (36 kDa, ●), H7P 
(43 kDa, ▲) and H11P (64 kDa, ▼). A 1 ml syringe with 20 G needle was used for injection at 
ambient temperature and 100 µl/sec. Injection forces for 64 kDa H11P are above upper 
detection limit; n=3 
Comparing injection forces of PMTs based on different DICs, 20 % H6P, M6P and B7P gels 
behave very similarly (Fig. 4.16), all showing acceptable peak injection forces of approx. 
26 N. The lower injection force found for B7P in comparison with H7P (approx. 42 N) 
correlates with the higher Tmax observed for B7P, making injection at ambient temperature 
easier. 
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Fig. 4.16: Injection force measurements of 20 % H6P (36 kDa, ●), H7P (43 kDa, ▲), B7P 
(42 kDa, ▼) and M6P (37 kDa, ■). A 1 ml syringe with 20 G needle was used for injection at 
ambient temperature and 100 µl/sec; n=3 
The addition of protein to H6P gels affected the injectability (Fig. 4.17). 15 % H6P gels with 
20 mg/ml IgG showed injection forces of up to 34 N, more than 20 N higher than 
protein-free 15 % H6P. For 20 % H6P injection forces exceeded the detection limit when 
20 mg/ml IgG were added.  
 
Fig. 4.17: Injection force measurements of 15 % H6P (36 kDa) gels with (▽) and without (▼) 
20 mg/ml IgG and 20 % H6P gels with (○) and without (●) 20 mg/ml IgG. A 1 ml syringe with 
20 G needle was used for injection at ambient temperature and 100 µl/sec. Injection forces 
for 20 % H6P with 20 mg/ml IgG are above upper detection limit; n=3 
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The strong increase in injection force cannot be explained by increased viscosity at ambient 
temperature as penetration resistance did not change at 21 °C (chapter 4.2.6). However, as 
will be discussed in chapter 5.1, IgG tends to precipitate in H6P gels at low and ambient 
temperatures. Hence, protein particles may block the needle, leading to increased injection 
force, but in situ-formed release samples generated from cooled (2-8 °C) gels (chapter 5.2.5) 
were injectable.  
  
 
5. PMT depots for controlled protein delivery 
In chapter 4 the physico-chemical properties of PMT 
poloxamer 403 derivatives such as H4P to H11P,
mechanical stability and decreased solubility compared to unmodified poloxamer 403. 
preliminary test pre-formed 20
FITC-Dextran 150 kDa. With the exception of H11P, 20
20 G needle at ambient temperatures.  However
indicating a risk of needle clogging as well as potential protein 
most promising PMT for controlled protein re
release and integrity, followed by
5.1. Protein precipitation in PMT systems
Fig. 5.1 illustrates particle formation and subsequent precipitation for lysozyme loade
20 % H6P gels with increasing lysozyme concentration, as well as a concentration series of 
H6P with 25 mg/ml lysozyme were chosen. The higher PMT and/or the protein 
concentration, the more pronounced the formation of visible particles became. 
 
Fig. 5.1: PMT systems with visible lysozyme precipitation (at the bottom of lower syringes). 
From left to right: 20 % H6P gel with 5, 15, 25 or 35
gel with 25 mg/ml lysozyme and 10, 15, 20 or 25
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After centrifugation protein was detected in both supernatant and precipitate, revealing 
100 % of the initial protein amount and, thus, indicating that precipitation is fully reversible. 
The supernatant has maintained thermo-responsive properties, but at 2-8 °C further particle 
formation could be seen. This indicates that the supernatant consists of a PMT-protein 
mixture. The precipitate was gel like from 2-8 °C to 42 °C, but dissolved within one hour 
when 0.5 ml cooled (2-8 °C) PBS were added. This dissolved precipitate showed 
thermo-responsive hardening as well, indicating an initial co-precipitation of PMT and 
protein. 
 
Fig. 5.2: Fraction of protein found in the precipitate after centifugation at 4 °C and 
re-dissolving in PBS at 2-8 °C for 1 h; n=1 
For increasing lysozyme concentration from 5 to 35 mg/ml in 20 % H6P gels increasing 
amounts of precipitated protein with approx. 8 % at 5 mg/ml and 41 % at 35 mg/ml were 
found (Fig. 5.2). In 20 % H6P 99 % of 20 and 81 % of 80 mg/ml IgG precipitated. The 
precipitated fraction of 25 mg/ml lysozyme increased with increasing H6P concentration 
from 10 to 25 %, yielding 10 and 75 %, respectively. For 20 mg/ml IgG 60 % precipitation 
were found at 10 % gel concentration, and 99 % at 20 % H6P. Hence, the precipitated 
protein fraction increases with increasing lysozyme concentration, but decreases with 
increasing IgG concentration. For both proteins, increasing gel concentration increases the 
precipitated fraction.  
20 % H6P with   5 mg/ml lysozyme
20 % H6P with 15 mg/ml lysozyme
20 % H6P with 35 mg/ml lysozyme
10 % H6P with 25 mg/ml lysozyme
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This protein precipitation can be both beneficial and disadvantageous at the same time. In 
general, protein precipitates need to dissolve prior to distribution in the human body, 
inducing potential sustained release properties [118]. The stability of a precipitated IgG after 
re-dissolution is already shown in literature [175]. However, precipitated protein can clog 
injection needles and hinder parenteral application (as seen in chapter 4.5). Furthermore, 
protein precipitation introduces potential quality issues: parenteral products have to 
maintain low number of particles matching pharmacopeia standards. If protein precipitates 
were insoluble, immunogenic, or simply inactive, they were a major drawback for the 
desired purpose of controlled protein release. This aspect will be discussed in more detail in 
chapter 5.3 
5.2. Release of IgG from PMT gels 
In literature, for e.g. poloxamer 407 [24, 106], different kinds of pNiPAAm co-polymers [120, 
179] as well as stearoyl-alanine oleogels [180] sustaining for some hours can be achieved. In 
other systems, e.g. photo-cross-linked HA-PEG co-polymers [181], PLGA-PEG-PLGA “ReGel®” 
[182] and pNiPAAm-PEG co-polymers [107], release periods can be prolonged to several 
days. Sustained release for up to several weeks is e.g. reported for PLGA-PEG-PLGA 
copolymers similar to ReGel® [108] as well as for photo-cross-linked thiol-PEG derivatives 
[183]. Bursts within 24 h as low as approx. 5 % using chain-elongated poloxamer 205 and 
304 systems [102] and PLGA-PEG-PLGA “ReGel®” systems [182] are reported. On the other 
hand, e.g. Zhuo et al. report 40 % BSA release within the first 24 h from their pNiPAAm-PEG 
gels [107]. Gong et al. found up to 80 % release within 24 h for a PEG-PCL-PEG system [176], 
and poloxamer 407 mixed with polysorbate 80 shows 40 % burst within 24 h as well [177]. 
However, this release data from literature is based on different drugs (some proteins, some 
peptides, some small molecules), different gel concentrations (ranging from approx. 10 to 
40 %), and different release conditions (different in vitro systems as well as in vivo 
experiments in rats, rabbits, etc.), leading to limited comparability in general. Furthermore, 
burst is an important feature in many controlled release platforms to initialize therapeutic 
levels in the first place [184].  
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In this thesis series of release experiments to determine the impact of PMT MW, 
concentration, employed diisocyanate, protein concentration, release temperature, depot 
formation technique and gel shelf-live were carried out. To compare release profiles, burst 
release after 24 h and time point of complete IgG release were determined. 
5.2.1. Impact of PMT molecular weight on IgG release 
20 % gels of poloxamer 403 (5.8 kDa), H4P (26 kDa), H6P (36 kDa), H7P (43 kDa) and H11P 
(64 kDa), representing a MW series of PMTs, with 20 mg/ml IgG were prepared and depots 
were pre-formed as described in chapter 2.2.11. Release from unmodified poloxamer 403 
was completed within 8 h (Fig. 5.3). 26 kDa H4P and 64 kDa H11P gels showed bursts of 34 
and 62 % after 24 h, respectively, and complete release at 7 d. 43 kDa H7P showed 33 % 
burst after 24 h with subsequent complete release within 21 d. The most pronounced 
sustaining of IgG release was achieved by 36 kDa H6P, as the burst was 29 %, and complete 
release was reached after 46 d.  
The lack of sustaining properties for unmodified poloxamer 403 correlates well with its fast 
dissolution rate and low mechanical strength. Poloxamer 403 gels are too soft and dissolve 
too rapidly to sustain IgG. Interestingly, although their gel strengths were very similar at 
37 °C (approx. 80 mN), substantial differences in IgG release were observed for the different 
PMTs. For H4P release time correlates with the gel dissolution time of one week.  For H11P a 
similar release period but increased burst was observed, although H11P gels did not dissolve 
within the investigated time frame. H6P and H7P gels showed further prolonged IgG release, 
and did not dissolve. This indicates that IgG was less efficiently entrapped in the gel matrix of 
H11P than in H6P or H7P. As already discussed in chapter 4, matrix formation and density 
are closely correlated to micelle interconnection and the most ordered and most densely 
packed matrix can be found at Tmax as analysed by penetration resistance. Considering that 
IgG leads to a decrease in Tmax for 20 % PMT gels, the following order of Tmax was found: 
H11P < H7P < H6P = 37 °C < H4P.  
 
59 
 
Fig. 5.3: Cumulative release of 20 mg/ml IgG from pre-formed 20 % depots of Poloxamer 403 
(5.8 kDa,○), H4P (26 kDa,■), H6P (36 kDa,●), H7P (43 kDa,▲) or H11P (64 kDa,▼) at 37 °C; 
n = 3 
Thus, H4P gels with Tmax > 37 °C have a less complete micelles network, triggering lower gel 
strength and faster dissolution. For H7P and most pronounced for H11P gels (Tmax < 37 °C) 
interconnected micelle networks were already partly molten at 37 °C, leading to less 
efficient protein entrapment than in H6P gels (Tmax =37 °C). PMT MW could therefore serve as 
trigger to set release periods on demand for days to weeks.  
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5.2.2. Impact of PMT concentration on IgG release 
Pre-formed depots with 20 mg/ml IgG from H6P gels with PMT concentration of 10, 15 and 
20 %, respectively, were generated and analysed. A strong dependency of release rates on 
PMT concentration was found (Fig. 5.4). As already discussed above, for 20 % H6P a burst of 
29 % and complete IgG release within 46 d were achieved. At lower gel concentration, IgG 
release was accelerated to 53 and 100 % burst for 15 and 10 % gels, respectively. IgG release 
was completed within 28 d for 15 % H6P gels, although gels were not dissolved at this time 
point. 
 
Fig. 5.4: Cumulative release of 20 mg/ml IgG from pre-formed H6P depots with 10 (●), 15 
(▲) or 20 (■) % gel concentration at 37 °C; n = 3 
Interestingly, there was no notable difference in gel volume between the different H6P 
concentrations and, thus, matrix density is lower for 10 and 15 % compared to 20 % gels. 
Furthermore, Tmax of H6P gels is shifted to higher temperatures by decreasing gel 
concentration and addition of IgG, being 37 °C at 20 % but > 37 °C for 15 and 10 % H6P gels. 
This results in further reduced matrix density for 10 and 15 % compared to 20 % gels, leading 
to faster IgG release and faster gel dissolution. For gels with Tmax < 37 °C, e.g. 20 % H7P and 
H11P, reducing gel concentration might lead to shift in Tmax closer to 37 °C and gel 
concentration may affect IgG release differently. 
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5.2.3. Impact of IgG concentration on release from PMT gels 
Drug concentration is reported to affect release rates of depot formulations [117, 154, 155]. 
At 5, 20 and 80 mg/ml IgG nearly identical release profiles with complete protein release 
after 46 d were observed (Fig. 5.5A). This corresponds to a total released protein mass of 
approx. 2.5, 10 and 40 mg (Fig. 5.5B) for the three different IgG concentrations, respectively. 
At 5 mg/ml a 24 h burst of 57 % (1.4 mg) was observed. For 20 mg/ml 29 % (2.9 mg) IgG, 
were found. Increasing protein concentration to 80 mg/ml the burst after 24 h was 19 % 
(7.6 mg).  
Interestingly, the fraction released within the first 24 h decreased with increasing IgG 
concentration. In chapter 4.2.6 for H6P a Tmax of 37 °C at 80 mg/ml IgG was found, leading to 
a more pronounced protein entrapment and, consequently, reduced burst release. As 
discussed in chapter 4.10, all PMT gels showed reversible protein precipitation. With 
increasing IgG concentration the precipitated fraction became smaller (99 % at 20 mg/ml 
and 81 % at 80 mg/ml). Therefore, if this precipitation was the main sustaining mechanism, 
for 20 mg/ml a more pronounced sustaining than for 80 mg/ml was to be expected. It can be 
concluded that IgG release is less governed by protein concentration and/or precipitation 
than by gel matrix structure. In contrast, many other hydrogel systems like pNiPAAm 
co-polymers offer limited protein loading (e.g. 90 to 95 % loading efficacy for 2 mg/ml insulin 
and even less for Angiotensin II, [120]) and a concentration dependent release within hours 
to days [9]. 
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Fig. 5.5: Cumulative release of 5 (■), 20 (●) or 80 (▲) mg/ml IgG from pre-formed 20 % H6P 
depots at 37 °C; A: released protein fraction; B: total protein mass released; n = 3 
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5.2.4. Impact of diisocyanate structure on IgG release 
Diisocyanate quality was found to strongly alter gel strength (chapter 4.2.3). Comparing 
36 kDa H6P and 37 kDa M6P at gel concentrations of 20 % with 20 mg/ml IgG each, M6P 
showed higher burst (37 vs. 29 %), and faster complete release (35 vs. 46 d) (Fig. 5.6). 
Comparing 42 kDa B7P and 43 kDa H7P, again at 20 % gel concentration and 20 mg/ml IgG 
each, B7P had lower burst (24 vs. 29 %) and longer overall release time (35 vs. 19 d).  
 
Fig. 5.6: Cumulative release of 20 mg/ml IgG from pre-formed 20 % H6P (●), M6P (■), H7P 
(▲) or B7P (▼) depots at 37 °C; in % of total IgG mass; n = 3 
More hydrophilic (smaller) diisocyanates led to higher Tmax and higher overall penetration 
resistance than more lipophilic (bigger) diisocyanates (chapter 4.2.3). Thus, compared to HDI 
systems, gels based on BDI linked PMTs have increased strength, and their Tmax is shifted to 
higher temperatures. In contrast, MDI based gels have reduced gel strength. As discussed in 
chapter 4.6.8, hardening profiles were furthermore affected by IgG as Tmax increased and 
overall penetration resistance decreased with protein load.  
For 20 % H6P gels IgG load shifted Tmax from approx. 34 °C to 37 °C, leading to a strong gel 
network, resulting in pronounced sustaining of protein release. 20 % M6P gels were found to 
have very similar Tmax values as H6P gels, but reduced overall gel strength, representing 
matrix density, leading to a slightly faster protein release compared to H6P gels. Protein-free 
20 % B7P gels showed a Tmax of 37 °C, but addition of IgG led to a shift in Tmax > 37 °C and 
therefore incomplete matrix formation at 37 °C. Compensation of this Tmax shift by reducing 
the gel concentration, B7P gels might offer enhanced sustaining properties.  
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5.2.5. In situ-formed PMT depots for controlled IgG delivery  
The aim of this thesis is to develop injectable in situ-forming depots for controlled protein 
delivery. Hence, release profiles of in situ-formed depots were investigated. As discussed in 
chapter 4.1, a rod-like structure was formed. As shown in Fig. 5.7 burst release of IgG within 
the first 24 h was approx. 30 % for both in situ-formed and pre-formed depots. IgG release 
from in situ-formed depots was completed after 26 d, compared to 46 d for pre-formed 
counterparts. 
 
Fig. 5.7: Cumulative release of 20 mg/ml IgG from pre-formed (●) or in situ-formed (■) 20 % 
H6P depots at 37 °C; n = 3 
No relevant difference in dissolution rate could be found comparing in situ-formed and 
pre-formed depots (chapter 4.3.8). This indicates that mechanical properties are 
independent of formation strategy. Increased IgG release rates could be explained by 
increased surface area of the worm-like structure compared to the condensed block 
structure of pre-formed depots. Interestingly, there is no increase in burst release upon in 
situ hardening. Hardening appears to be fast enough to prevent significant solution of drug 
and/or thermo-polymer immediately after injection into 37 °C warm media. This is an 
outstanding property of PMT gels, as other hydrogels with a hardening upon injection 
principle show higher bursts and overall faster release. E.g. pNiPAAm-PEG gels with 40 % 
BSA burst release, [107]. A PEG-PCL-PEG system with up to 80 % burst release [176], and 
poloxamer 407 mixed with polysorbate 80 showing 40 % burst within 24 h [177]. 
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5.2.6. IgG release from PMT depots at different temperatures 
PMT gels undergo thermo-reversible hardening and melting. This is caused by formation and 
subsequent deformation of a coherent micellar network. Network density and/or micelle 
interconnectivity are highest at a specific Tmax values. Tmax depends on PMT MW, 
concentration and hydrophilicity, as well as on protein load. For concentration and MW 
series of PMT IgG release was slowest for systems with Tmax of, or at least close to, 37 °C. For 
20 % H6P gels with 20 mg/ml IgG mechanical strength decreased at temperatures below or 
above 37 °C (= Tmax). As shown in Fig. 5.8 this also affected IgG release: at 35 °C and 39 °C the 
24 h burst was increased to 38 % and 47 %, with completed IgG release after 40 or 26 d, 
respectively.  
 
Fig. 5.8: Cumulative release of 20 mg/ml IgG from pre-formed 20 % H6P depots at 35 (■), 37 
(●) or 39 (▲) °C; n = 3 
As shown before, IgG release was most effectively sustained at or close to Tmax of the 
corresponding gel system. Release at temperatures higher than Tmax is faster than for 
temperatures below Tmax, indicating that matrix melting affects matrix density more than yet 
incomplete matrix formation.  
Overall, increased body temperature, e.g. due to local inflammation, may accelerate IgG 
release from 20 % H6P depots with their Tmax of 37 °C. At the same time increased body 
temperature could slow down protein release for lower MW PMT depots or less 
concentrated H6P gels with Tmax values < 37 °C . 
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5.2.7. Impact of PMT gel shelf-life on IgG release  
As discussed in chapter 1.3.2 PMTs contain urethane groups. These urethane groups can be 
hydrolyzed, generating smaller PMT derivatives and/or poloxamer. In vivo, this mechanism 
should lead to depot dissolution and subsequent polymer extraction by the kidneys. Also, a 
potential degradation of PMTs prior to depot formation may affect MW and, hence, both 
dissolution and release rate. Therefore, a 20 % H6P gel with 20 mg/ml IgG was prepared and 
stored at 2-8 °C for 15 weeks and subsequently IgG release from a pre-formed depot was 
monitored at 37 °C. As seen in Fig. 5.9 the release was not significantly changed (p = 0.05), 
and potential H6P hydrolysis upon storage appears to have no impact on the sustaining 
properties of the derived hydrogels. 
 
Fig. 5.9: Cumulative release release at 37 °C of 20 mg/ml IgG from approx. 0.5 g pre-formed 
20 % H6P depots from freshly prepared gel (■) or gel stored for 15 weeks at 2-8 °C (▲); n = 3 
IgG almost completely precipitated in 20 % H6P gels at 2-8 °C, and the protein was actually 
stored in a precipitated state for 15 weeks. Interestingly, still complete IgG release was 
observed and HPSEC analysis showed no indication for the formation of protein aggregates. 
It can be concluded that IgG precipitation in PMT gels is reversible, even after 15 weeks.  
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5.3. Integrity of released IgG 
In order to serve as controlled release system PMT gels and depots have to maintain protein 
integrity. Chapter 5.1 already discussed protein precipitation in PMT systems. Depending on 
several parameters, including protein quality and concentration of both protein and PMT, up 
to 99 % protein were found in the precipitate. However, all precipitates redissolved upon 
mixing with PBS. Despite initial precipitation, IgG was released completely for all PMT 
systems investigated. In HPSEC, neither soluble aggregates nor fragments were found. Even 
storing the precipitate for 15 weeks in an aqueous system at 2-8 °C led to the same results 
(chapter 5.2.7). 
To further proof the integrity of released IgG this chapter summarizes results from visual 
inspection, HPSEC, and light obscuration, turbidity and intrinsic fluorescence. Pre-formed 
20 % H7P depots with 20 mg/ml IgG were chosen as candidates as they released approx. 
3.3 mg IgG within the final 13 days of the release period and the shortened time frame for 
H7P release compared to H6P reduced measurement time. Furthermore, two controls were 
tested (i) pre-formed placebo 20 % H7P depots, representing particles and noise generated 
by the thermo-polymer itself; (ii) pre-formed placebo 20 % H7P depots with additional IgG 
spiked at 0.5 mg/ml immediately after PBS addition, representing particles and other species 
formed by IgG under the given release conditions in presence of PMT, but without initial 
protein precipitation and release from a gel depot. 
5.3.1. Visible particles 
Release samples as well as all control samples were free of visible particles after 1 d, 1 week 
and 3 weeks. After three weeks in one sample and one control sample particles deriving 
from disintegration of the PMT depots were noticeable. 
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5.3.2. Turbidity 
For IgG release samples a turbidity of 0.77 ± 0.27 FNU was found after 3 weeks. At the same 
time point control samples showed a turbidity of 0.72 ± 0.52 (IgG spiked) and 0.28 
± 0.07 (H7P placebo) FNU, respectively. Overall, turbidity values were low, and IgG release as 
well as spiked IgG samples showed no significant difference (p = 0.01). The overall low 
turbidity correlates well with visual observation of clear, nearly particle free solutions and 
indicates the absence of IgG aggregates. 
5.3.3. SEC analysis 
All IgG peaks detected for release and control samples represent monomers. They are 
symmetrical with no relevant tailing or fronting. No fragment or aggregate peaks can be 
seen. Of course, placebo samples show no protein peak at all.  
5.3.4. Subvisible particles 
In all samples subvisible particles were formed. For release samples 61,820 ± 1,220 particles 
> 1 µm were found in the 20 ml release medium, with 1,440 ± 1,740 (2.3 %) of them > 10 µm 
and 260 ± 280 (0.4 %) > 25 µm. In IgG spiked samples 36,880 ± 800 particles > 1 µm, 140 ±60 
(0.4 %) > 10 µm and 40 ±20 (0.1 %) > 25 µm were detected. In H7P placebo samples 
9,800 ± 540 particles > 1 µm were detected, among them 120 ± 20 (1.2 %) > 10 µm and 
40 ± 0 (0.4 %) > 25 µm.  
Subvisible particles were detected by HPSEC and light obscuration, as described in chapters 
2.2.5 and 2.2.8. For both measurements portions of turbidity samples (chapter 2.2.14) were 
used. Furthermore, all IgG release data was derived from HPSEC; but only these special 
samples were generated under continuous laminar air-flow conditions. 
Table 5.1 shows subvisible particles as analysed by light obscuration. Numbers represent 
calculated total particle counts in the entire PBS volume of 20 ml. It can be seen that for  
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Table 5.1: Subvisible particles as determined by light obscuration of samples drawn after 
3 weeks release under LAF conditions. Numbers represent extrapolated values for the entire 
20 ml release medium. Release sample is 0.5 g pre-formed 20 % H7P with 20 mg/ml IgG in 
20 ml PBS at 37 °C, control samples are analogous H7P placebo gels, one of them with 
additional IgG spiking to yield protein concentration of 0.5 mg/ml; n = 3 
Total numbers of particles > 1 µm as well as > 10 µm were significantly higher for release 
samples than for IgG spiked controls (p = 0.01). The same holds true for particles > 1 µm in 
IgG spiked controls compared with H7P placebo samples (p = 0.01). All other differences are 
non-significant (p = 0.05). The increased particle numbers compared to placebo correspond 
to increased turbidity values. Considering H7P derived particles nearly identical in all 
samples (justified by the very low sd for placebo samples), the number of proteinaceous 
particles can be estimated: in release samples approx. 52,000 particles > 1 µm,  1,300 
> 10 µm and 200 > 25 µm might originate from IgG. In IgG spiked control samples approx. 
27,000 particles > 1µm, but none > 10 or 25 µm might be proteinaceous.  
As proteinaceous particles have to be considered potentially immunogenic [178], according 
to Ph.Eur. 2.9.19 liquids for injection may contain only up to 6,000 particles > 10 µm. Hence, 
even if all particles were to be released simultaneously, 20 % H7P depots with 20 mg/ml IgG 
meet Ph.Eur. criteria. Thus, protein aggregation is no relevant issues for IgG release from 
H7P gels. As all gels showed similar protein precipitation as well as complete IgG release, this 
trend is well generalized for other PMTs. 
  
Particle fraction 
[µm]
>1 >10 >25
Release sample 
medium
 61820 ± 1220 1440 ± 1740 260 ± 280
IgG spiked 
control medium
36880 ± 800 140 ± 60 40 ± 20
H7P placebo 
control medium
9800 ± 540 120 ± 20 40 ± 0
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5.3.5. Intrinsic fluorescence 
Measuring intrinsic fluorescence no differences between freshly diluted IgG stock solution 
(0.5 mg/ml) and release medium after 3 weeks could be seen (Fig. 5.10), representing 
maintained secondary protein structure.  FTIR as orthogonal method could not be used due 
to interference of the urethane signals of dissolved PMT.  
 
Fig. 5.10: Intrinsic fluorescence of freshly prepared 0.5 mg/ml IgG solution (△) and release 
samples of 20 mg/ml IgG from pre-formed 20 % H6P depots after three weeks (●); n = 3. To 
render graphs visible, not all data points are shown.  
5.4. Chemical stability of H7P 
Dissolution experiments showed that H7P depots are stable at physiological pH and 
temperature for several months (chapter 4.3). Gels can be prepared several weeks prior to 
application and stored at 2-8 °C without negative impact on release properties 
(chapter 5.2.7). To further characterize the polymer stability, GPC analysis was performed. 
Dry H7P and autoclaved H7P, H7P dissolved in either PBS, 0.5 M HCl or 0.5 M NaOH after 7 d 
at 40 °C and after 3 d at 90 °C were analysed. 
Naive H7P yielded a MW of 43.8 kDa (table 5.2), which is in good accordance to 43 kDa as 
specified by the provider. Approx. 80 % material was lost from the autoclaving bag during 
the autoclaving process of H7P, leaving polymers with an increased MW of 51.5 kDa as 
smaller MW fractions of H7P dissolve and hydrolyse more readily. Incubation at 40 °C for one 
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week showed no impact on MW as 44.1, 45.6 and 43.1 kDa were found in PBS, HCl and 
NaOH, respectively. Increasing incubation temperature to 90 °C, however, led to strong MW 
losses to  27.2 kDa in PBS, 3.3 kDa in HCl and a MW below the detection limit for NaOH 
samples. 
 
Table 5.2: MW of naive and temperature-treated H7P as determined by GPC.; n = 1 
The decrease in MW is mainly induced by hydrolysis of urethane groups, forming  poloxamer 
unimers [123]. Even after 121 °C for 15 min a high MW fraction remained, suggesting that 
small MW fractions hydrolyse more readily. Incubation at 40 °C for 7 d indicates good PMT 
stability, even at extreme pH values of 0.3 (HCl) and 13.7 (NaOH). This is in accordance to the 
dissolution experiments as PMT depots remain stable for months rather than weeks. At 
90 °C PMT degrade substantially and, as expected for urethane groups, this cleavage was 
much more pronounced at pH 0.3 and 13.7 than at 7.2 [123]. Hence, PMTs are fairly stable 
under relevant storage, application and release conditions. 
  
H7P manipulation MW [kDa]
- 43.8
autoclaving 51.5
7 d incubation at 40 °C in PBS 44.1
7 d incubation at 40 °C in 0.5 M HCl 45.7
7 d incubation at 40 °C in 0.5 M NaOH 43.1
3 d incubation at 90 °C in PBS 27.3
3 d incubation at 90 °C in 0.5 M HCl 3.3
3 d incubation at 90 °C in 0.5 M NaOH -
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6. Summary and outlook 
6.1. In situ cross-linked HA gels 
Several chemically cross-linked hydrogels are reported as promising controlled release 
platforms [5, 21, 55, 150, 151]. Among these, the derivatization and cross-linking of HA by 
means of azide-alkyne cycloaddition is specifically interesting [49, 81, 82]. In an effort to test 
this approach for protein delivery the degree of HA substitution achieved was below the 
values reported in literature. Formation of high-molecular weight species could be shown by 
HPSEC and centrifugation experiments. At the same time, a significant amount of unreacted 
small MW species remains due to the low DoS. Furthermore, the cross-linking achieved is not 
sufficient to form a gel structure with increased viscosity and reduced water solubility 
compared to unmodified HA. The impact of linker size and concentration, as well as the 
actual release profiles of proteins from the cross-linked HA could not be investigated as no 
functioning controlled release system is generated. Possibly, simultaneous cleavage of HA by 
the Cu-(II)/ascorbic acid system [134] competes with cross-linking.  
To make the system suitable for the task of in situ formation of controlled release systems 
for protein pharmaceutics the DoS of the derivatized HA and the degree of cross-linking have 
to be increased. With this new material an increase in viscosity and a decrease in water 
solubility should be possible. A more water soluble linker could introduce more flexibility in 
the experimental design. Transition to copper-(I) or, preferably, copper-free protocols is 
highly recommended to sustain protein integrity within the in situ gelling system. This 
would, at the same time, entirely prevent HA cleavage by Cu-(II)/Ascorbic acid. Also other 
click reactions to cross-link HA are interesting alternatives [152]. 
Overall, the discussed system of cross-linking HA by the azide-alkyne cycloaddition offers 
great potential. However, there are many complex parameters to be set and characterized: 
the initial MW and concentration of the HA, the derivatization procedure, the catalytic 
system used, linker concentration, size and solubility, as well as potential cleavage reactions 
and protein integrity. Setting all these parameters correctly, to achieve a functional 
controlled release system for protein pharmaceutics, requires a deeper understanding of the 
entire system. 
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6.2. Thermo-responsive PMT gels 
PMTs are amphiphilic block-co-polymers generated by chain-elongation of poloxamers with 
diisocyanates. Similar to unmodified poloxamer, PMTs form micelles. These micelles 
interconnect and rearrange into higher molecular structures to form defined hydrogel 
networks. This sol-gel transition occurs over approx. 10 °C between 25 to 35 °C, for e.g. 20 % 
H6P (36 kDa MW).  
A series of different PMTs with different MW, poloxamer quality and diisocyanate quality are 
studied, introducing different hydrophilicity, gel formation, clouding and dissolution 
properties. PMT gels offer promising thermo-responsive hardening profiles in the desired 
temperature range between ambient temperature and body temperature. Gels are generally 
injectable using 20 G needles at ambient temperature and offer acceptable mechanical 
strength > 1 kPa by many PMT qualities at concentrations higher than 10 %. Gels of 
poloxamer 403 based PMTs remain stable in PBS at 37 °C for several weeks, followed by slow 
dissolution. Poloxamer 407 based PMTs dissolve within hours to days. Increasing MW or PMT 
concentration lead to increased gel hardness, shifting gel formation to lower temperatures. 
Using BDI as linking diisocyanate leads to harder gels and shifts in hardening profiles to 
higher temperatures compared to HDI based PMTs. MDI linkage reduces gel strength, but 
does not lead to similar temperature shifts as BDI. In general, with higher gel strength the 
dissolution rate for poloxamer 403 PMTs decreases. Addition of PEG can be used to adjust 
hardening and gel dissolution.  Addition of high protein amounts increases the temperature 
of highest mechanical strength, Tmax, but does not negatively impact the gel strength at 
37 °C. 
Several PMTs showed promising release profiles for IgG over several days to weeks with a 
burst release of up to 30 % within 24 h. The delay in release at body temperature was most 
pronounced for systems with Tmax values close to 37 °C. This target was matched by 20 % 
H6P gels with 20 mg/ml IgG. Other potential candidates include H4P, H7P, B7P and M6P gels 
at 20 %. Also other gel concentrations might be applicable, esp. for high MW PMTs like H7P, 
H8P or even H11P. For H6P systems manual injection through 20 G needles could be easily 
performed, leading to in situ-formed depots with also strongly pronounced sustaining 
properties. Very high protein concentrations of up to 80 mg/ml IgG could be effectively 
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delivered. Furthermore, for H6P, sustained release of Lysozyme and 150 kDa FITC-Dextran 
were shown as well. These latter two substances were released faster than IgG and other 
PMTs at different concentrations might be beneficial. This makes PMT gels a very promising 
and competitive sustained release system. 
Both proteins showed marked but reversible precipitation in all PMT gels tested, while 
FITC-Dextran remained soluble. This precipitation might add to the sustaining properties of 
PMT depots, but matrix diffusion remains the key parameter as indicated by the strong 
impact of Tmax shifts. As the PMT depots dissolved slowly under physiological conditions, 
depot erosion played only a minor role in release profiles. Lasting months rather than weeks 
at 37 °C in vitro, 20 % PMT depots might actually be too stable as their half-life in the body 
might be months to years. Optimizing gel concentration, PMT MW and additives like PEG can 
be used to increase dissolution rates. 
Throughout all release experiments, despite the initial protein  precipitation in PMT gels, no 
indication for instability of IgG in PMT gels or upon release was found. No proteinaneous 
visible particles and only a minimal number of subvisible particles were released from the gel 
matrix. Neither increased turbidity, nor soluble aggregates or fragments as determined by 
HPSEC, nor changes in intrinsic fluorescence were observed. At the same time, PMT 
polymers and gels were fairly stable at 2-8 °C, under relevant physiological conditions and at 
40 °C.  
All in all, PMTs are a promising system for injectable in situ hardening hydrogels for 
controlled protein delivery. As release periods can be set between days to weeks by 
choosing the correct PMT system, both local and systemic sustained release should be 
possible. 
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